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Endometrial cancer is a relative common malignant disease among 
postmenopausal women in Denmark. Early diagnose and advanced robot-
assisted laparoscopic surgery contributes to high survival rates. The reported 
health-related quality of life following surgery for endometrial cancer is high 
with corresponding low risk of psychosocial and physical long-term effects. 
Nevertheless, any surgical procedure entails a risk of adverse outcome, like 
chronic postoperative pain. Chronic postoperative pain decreases the quality 
of life for the affected patients and poses a significant challenge in the 
analgesic management for us as clinicians. Chronic postoperative pain is the 
end product of a complex cascade of interactions between neuronal 
pathophysiologic processes, comorbidity, psychological traits and 
socioeconomic factors. Evidence suggest that a range of preoperative risk 
factors might increase the susceptibility to development of chronic 
postoperative pain, like pre-existing pain conditions, socioeconomic 
disadvantage and certain serologic compositions of lipids and lipoproteins. 
Furthermore, some evidence indicate that preoperative quantitative sensory 
testing can identify patients at risk of developing chronic postoperative pain. 
   
If we as clinicians had a better understanding of some of these risk factors - 
or even could identify patients at risk - we could counsel our patients better 
prior to surgery, and conceivably even reduce the risk of developing chronic 
postoperative pain through interventions and clinical trials. The overall aim of 
this PhD dissertation was to investigate some of the many aspects of chronic 
postoperative pain following surgery for endometrial cancer: What is the 
prevalence? What are the risk factors? Can the development of chronic 
postoperative pain be predicted? To answer these questions, we conducted 





The first study was a questionnaire-based study among two-hundred-and-
seven patients treated for endometrial cancer at Aalborg University Hospital 
from January 1st, 2010 till July 31st, 2015. The prevalence of chronic 
postoperative pain was 14.9% (95% CI 10.4-20.6). Preoperative pelvic pain 
and a high level of acute postoperative pain were shown to be independent 
risk factors for development of chronic postoperative pain with an OR of 4.99 
(95% CI 4.15-5.83) and 1.27 (95% CI 1.09-1.45), respectively. 
 
The second study was a nested, case-control study, where seventy-eight 
preoperative blood samples from The Danish Cancer Biobank were analyzed 
by means of nuclear magnetic resonance spectroscopy. Here, we 
hypothesized that patients who developed chronic postoperative pain had a 
distinctive preoperative serologic composition of lipids and lipoproteins, 
compared to patients who did not develop chronic postoperative pain. The 
results demonstrated that we could not discriminate between these two 
groups when including all risk assessments groups - nor could we predict the 
development of chronic postoperative pain. 
 
The third study was a longitudinal, observational cohort study of one-hundred-
and-forty patients treated for endometrial cancer from August 1st, 2015 till 
December 31st, 2018. The prevalence of chronic postoperative pain was 
13.6% (95% CI 8.4-20.4) and preoperative pelvic pain again showed to be an 
independent risk factor with an OR of 6.62 (95% CI 2.26-19.44). In this study, 
we further hypothesized that preoperative quantitative sensory testing could 
predict development of chronic postoperative pain, which was rejected. 
 
Through the studies presented in this PhD dissertation we add valuable new 
insights to the existing knowledge on chronic postoperative pain after robot-







Endometriecancer er en relativ hyppig kræftform blandt danske kvinder efter 
overgangsalderen. Tidlig diagnosticering og avanceret behandling i form af 
robot-assisteret laparoskopisk kirurgi bidrager til en høj overlevelsesrate. Den 
sundhedsrelaterede livskvalitet efter kirurgi for endometriecancer er høj, mens 
risikoen for psykosociale og somatiske mén er tilsvarende lav. På linje med al 
anden kirurgi kan robot-assisteret laparoskopisk kirurgi dog medføre 
uønskede bivirkninger, såsom kronisk postoperativ smerte. Kronisk 
postoperativ smerte nedsætter livskvaliteten for de ramte patienter, og den 
smertestillende behandling udgør en betragtelig klinisk udfordring. Kronisk 
postoperativ smerte er resultatet af en kompleks kaskade af interaktioner 
mellem neurale patofysiologiske processer, komorbiditet, psykologiske 
karaktertræk og socioøkonomiske faktorer. Forskningsresultater indikerer, at 
en række præoperative risikofaktorer måske kan øge modtageligheden for 
udvikling af kronisk postoperativ smerte, såsom præeksisterende 
smertetilstande, lav socioøkonomisk status samt visse serologiske 
sammensætninger af lipider og lipoproteiner. Derudover viser nogle 
forskningsresultater, at patienter i risiko for udvikling af kroniske postoperative 
smerter kan identificeres præoperativt ved hjælp af kvantitative sensoriske 
testmetoder.  
   
Hvis vi som klinikere havde en bedre forståelse for disse risikofaktorer - eller 
ligefrem kunne identificere risikopatienter - da kunne vi give en bedre 
præoperativ rådgivning. Endvidere kunne vi muligvis reducere risikoen for 
udvikling af kroniske postoperative smerter via interventioner og kliniske 
forsøg. Det overordnede formål med denne PhD afhandling var at belyse 
nogle af de mange aspekter af kroniske postoperative smerter: Hvad er 
prævalensen? Hvilke risikofaktorer er der? Kan man forudsige, hvem der 
udvikler kroniske postoperative smerter? For at besvare disse spørgsmål, 
gennemførte vi tre studier af kroniske postoperative smerter, som 
præsenteres i denne PhD afhandling. 
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Det første studie var et spørgeskema-baseret studie af to-hundrede-og-syv 
patienter behandlet på Aalborg Universitetshospital i perioden fra 1. januar 
2010 til 31. juli 2015.  Prævalensen af kronisk postoperativ smerte var 14,9% 
(95% CI 10,4-20,6). Tilstedeværelsen af præoperative bækkensmerter samt 
et højt akut postoperativt smerteniveau var begge signifikante risikofaktorer 
for udvikling af kronisk postoperativ smerte med en OR på henholdsvis 4,99 
(95% CI 4,15-5,83) og 1,27 (95% CI 1,09-1,45). 
 
Det andet studie var et case-kontrol studie, hvor otte-og-halvfjerds præ-
operative blodprøver fra den Danske Cancer Biobank blev analyseret med 
nuklear magnetisk resonansspektrografi. Her var vores hypotese, at patienter 
der udviklede kroniske postoperative smerter, havde en distinkt præoperativ 
serologisk sammensætning af lipider og lipoproteiner, sammenlignet med 
patienter, der ikke udviklede kroniske postoperative smerter. Resultaterne 
viste, at vi ikke kunne skelne disse patientgrupper fra hinanden, når vi 
inkluderede patienter fra alle risikokategorier - ej heller kunne vi forudsige 
udvikling af kronisk postoperativ smerte. 
 
Det tredje studie var et longitudinelt observationsstudie af ét-hundrede-og-
fyrre patienter behandlet på Aalborg Universitetshospital i perioden fra 1. 
august 2015 til 31. december 2018. Prævalensen af kronisk postoperativ 
smerte var 13,6% (95% CI 8,4-20,4) og tilstedeværelsen af præoperative 
bækkensmerter viste sig atter som en signifikant risikofaktor for udvikling af 
kronisk postoperativ smerte med en OR på 6,62 (95% CI 2,26-19,44). I dette 
studie var vores hypotese endvidere, at kvantitative sensoriske testmetoder 
kunne identificere patienter i risiko for udvikling af kroniske postoperative 
smerter, hvilket ikke var tilfældet. 
 
Studierne i denne PhD afhandling tilføjer værdifuld ny viden om kronisk 
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CHAPTER 1. BACKGROUND 
1.1. ENDOMETRIAL CANCER 
1.1.1. EPIDEMIOLOGY 
Malignant neoplasm of the endometrium is the fourth most common cancer 
among women in Western Europe and the United States of America4. The 
incidence in Denmark is approximately 800 cases per year and an age-
standardized incidence rate of 13.5 per 100,000 persons / year5. Endometrial 
cancer predominately affects 
postmenopausal women with 
an incidence peak at 70 to 75 
years of age5 (fig. 1). 
Endometrial cancers can be 
classified by the FIGO 
(Fédération Internationale de 
Gynécologie et d’Obstétrique) 
stage and the clinical and 
histologic type6,7 (see section 
1.1.2. and 1.1.3.). More than 
75% of the Danish cases are 
diagnosed in FIGO stage I with a 5-year survival of 85.1%8. The overall 5-year 
survival for all FIGO stages is 75.5%8. When stratifying mortality rates by the 
classification in type I and II tumors, Gustafson et al recently found that the 
mortality rate for type I tumors in Denmark had declined in the time period 
from 2002-2015 with an annual percent change of -2.3 (95% CI -3.9, -0.7) and 
a 5-year survival rate of 89.8% (95% CI 89.0-90.5)9. In contrast, the authors 
found that the mortality rate for type II tumors had increased in the same time 
period with an annual percent change of +5.9 (95% CI 3.0-8.9) and a 5-year 
survival rate of 57.2% (95% CI 54.0-60.3)9. 
 
Figure 1: The age-related incidence of endometrial 
cancer in Denmark in 2016. Reprint from NORDCAN 




Endometrial cancers are a diverse group of neoplasms which differ in 
pathophysiology. A classification can either be based on the clinical 
manifestations in type I and II tumors - or by the histopathologic 
characteristics; the latter will be described in section 1.1.3. 
 
The estrogen-dependent tumors 
(type I, endometrioid) account 
for approximately 90% of the 
endometrial cancers10 (fig. 2). 
Atypical endometrial hyperplasia 
is considered as a precursor 
lesion, which over time may 
progress to endometrial cancer 
in 5-25% of the cases11.  
Glandular and stromal hyper-
plasia of the endometrium is 
stimulated by estrogen12.  
Consequently, unopposed long term estrogen stimulation, obesity, early 
menarche and late menopause all increase the risk of endometrial cancer12. 
 
The second group of tumors (type II, non-endometrioid) accounts for less than 
10% and mainly consists of the serous, mucinous and clear cell 
adenocarcinomas, which can arise from an atrophic endometrium and are 
largely estrogen-independent13.  Type II tumors are more aggressive in their 
clinical behavior; even though they comprise only 10% of the endometrial 
cancers, they account for more than 40% of deaths from the disease14,15. 
  
Figure 2: Uterus with endometrial cancer.  
Used with permission of MAYO Foundation for 




1.1.3. CLASSIFICATION AND STAGING 
Endometrial cancer is a malignant epithelial tumor which can be classified by 
histopathological characteristics into endometrioid carcinomas (the vast 
majority endometrioid adenocarcinomas) and other epithelial carcinomas 
(serous, mucinous and clear cell adenocarcinomas)10,16,17. The endometrioid 
adenocarcinomas can furthermore be classified based on the degree of 
glandular differentiation in grade 1 (≤5% solid non-glandular growth), grade 2 
(from 6% to 50% solid non-glandular growth) and grade 3 (>50% solid non-
glandular growth)18. Other rare types of uterine cancer include mesenchymal 
tumors and mixed epithelial- and mesenchymal tumors19,20. Subtypes of the 
latter group of tumors are carcinosarcomas, which consist of both a malignant 
carcinomatous and a sarcomatous component - and adenosarcomas, which 
consist of a benign epithelial component and a sarcomatous component19,20. 
In the clinical setting, carcinosarcomas are classified along with the 
carcinomas, since they share similar risk factors and are treated alike21. The 





    Endometrioid carcinomas  
          Endometrioid adenocarcinomas 
                Grade 1 
                Grade 2 
                Grade 3 
    Mucinous adenocarcinomas                                   
    Serous adenocarcinomas                                   
    Clear cell adenocarcinomas  
 
Mesenchymal tumors 
    Leiomyosarcoma 
   
Mixed epithelial and mesenchymal 
tumors 
    Carcinosarcomas                
    Adenosarcomas 
 
FIGO stages 
I: Tumor confined to the uterus 
       IA: <50% myometrial invasion 
       IB: ≥50% myometrial invasion 
II: Tumor invades the cervical stroma but does not  
    extend beyond the uterus. 
III: Local or regional spread of tumor 
IIIA: Serosal or adnexal invasion 
IIIB: Vaginal or parametrial involvement 
       IIIC: Metastasis to pelvic or paraaortic  
             lymph nodes. 
         IIIC1: Pelvic lymph node involvement 
         IIIC2: Paraaortic lymph node involvement 
IV: Extension to the pelvic wall, lower one-third of  
     the vagina or hydronephrosis or nonfunctioning  
     kidney. 
       IVA: Invasion of bladder or bowel mucosa. 
       IVB: Distant metastases, including abdominal  
              or involvement of inguinal lymph nodes. 
 
Table 1: Histopathologic classification according to WHO (World Health Organization)10 and 
staging according to FIGO (Fédération Internationale de Gynécologie et d’Obstétrique)18,22. 
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1.1.4. DIAGNOSIS AND TREATMENT 
The predominant symptoms of endometrial cancer are postmenopausal 
vaginal bleeding or menometrorrhagia in the premenopausal patients10. The 
diagnosis is based on histologic examination of an endometrial biopsy. The 
treatment in early stage disease is surgical with hysterectomy and bilateral 
salpingo-oophorectomy23. The removal of pelvic and / or paraaortic lymph 
nodes does not improve survival, but is solely done for staging purposes24,25. 
In case of stage III or IV disease, the standard adjuvant treatment in Denmark 
consists of chemotherapy with carboplatin and paclitaxel, while radiotherapy 
is rarely applied, as studies have shown radiotherapy fails to increase the 
overall survival, yet increasing the treatment-related morbidity26–29. 
 
During the last decade, the technological innovation has shifted the procedure 
from open access surgery and laparoscopic minimally invasive surgery to 
robot-assisted minimally invasive surgery (RMIS). The introduction of RMIS in 
gynecology in Denmark began in 2008 at Aalborg University Hospital and 












Figure 3: The introduction of Robot-assisted Minimally Invasive Surgery (RMIS) in Denmark from 
2008 to 2015. Open Access Surgery (OAS), Laparoscopic Minimally Invasive Surgery (LMIS). 
Reprint from Long term resource consequences of a nationwide introduction of robotic surgery 




Studies have shown an association between the introduction of RMIS in the 
surgical treatment of early stage endometrial cancer and improved survival 
rates and reduced risk of severe complications30,32,33. In respect to surgical 
training, Lim et al found that RMIS had a steeper learning curve for 
hysterectomy with lymphadenectomy when compared to open access surgery 
and laparoscopic minimally invasive surgery34. Finally, the Robot-Assisted 
Surgery for High-Risk Endometrial Cancer (RASHEC) trial showed non-
inferiority in paraaortic lymphadenectomy, shorter length in hospital stay, and 
lower total cost for RMIS over open access surgery in high risk cases of 
endometrial cancer35.  
 
Different treatment strategies have been applied over the course of time. At 
the first joint consensus conference of The European Society for Medical 
Oncology (ESMO), The European Society of Gynecological Oncology 
(ESGO) and The European Society for Radiotherapy and Oncology (ESTRO) 
in 2014, a treatment algorithm for lymphadenectomy was agreed upon36: The 
patients were to be preoperatively stratified into risk categories based on 
histologic type and grade: The low risk cases (endometrioid adeno-
carcinoma with grade 1 or 2 and superficial myometrial invasion <50%) should 
be treated with hysterectomy and bilateral salpingo-oophorectomy;  
intermediate risk cases (deep myometrial invasion >50% or grade 3 superficial 
myometrial invasion <50%)  with optional, additional lymphadenectomy and in 
high-risk cases (grade 3 with deep myometrial invasion >50% and all non-
endometrioid types) lymphadenectomy was recommended36. 
 
Comprehensive lymphadenectomy, however, has an inherent risk of 
perioperative bleeding, nerve damage and postoperative lymphedema37,38. In 
an effort to minimize the risk of these complications, Abu-Rustum and 
colleagues at Memorial Sloan Kettering Cancer Center introduced a treatment 
algorithm for removal of sentinel lymph nodes (SLN) during RMIS by 
intraoperative mapping using near-infrared fluorescence after cervical 
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injection of indocyanine-green dye39,40. The SLN algorithm, which has since 
been adopted by many centers, has been shown to decrease the incidence of 
lymphoedema and other major postoperative complications while having a 
high degree of diagnostic accuracy41–43. 
 
1.1.5. HEALTH-RELATED QUALITY OF LIFE 
As endometrial cancer is a relatively common cancer with high survival rates, 
the accumulated number of long-term survivors is correspondingly high44. 
Seeing that both endometrial cancer and its treatment can be debilitating, the 
need to consider the impact on the Health-Related Quality of Life (HRQoL) 
has become increasingly evident. Consequently, HRQoL has become an 
integrated part of the evaluation of therapeutic interventions45. Several 
validated questionnaires have been developed for this purpose, e.g. The 
Medical Outcomes Study Short-Form (SF-36) questionnaire and The Quality 
of Life Questionnaire (QLQ-C30) from The European Organization for 
Research and Treatment of Cancer (EORTC)45,46.  
 
While SF-36 is a general measure of HRQoL, the QLQ-C30 is cancer specific 
and incorporates functional scales (physical, role, cognitive, emotional, and 
social), symptom scales (fatigue, pain, and nausea/vomiting), global health 
status scale, and finally a number of items assessing cancer related 
symptoms45. Furthermore, a supplementary questionnaire module concerning 
endometrial cancer has been developed by the EORTC, entitled QLQ-EN2447. 
 
A literature search of HRQoL studies on endometrial cancer performed over 
the last two decades found 7 studies using the SF-36 questionnaire48–54, 4 
studies using the QLQ-C30/EN24 questionnaire44,55–57 and 1 study using the 
SF36 and the QLQ-EN24 questionnaires in combination58. The majority of 
these studies compare the HRQoL in series of surgery (open access surgery 
or laparoscopic minimally invasive surgery) versus surgery and adjuvant 
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radiotherapy44,52,56–58, while others evaluate the effect on HRQoL of physical 
activity, lifestyle changes and mental health49–51. Overall, endometrial cancer 
patients report high scores of HRQoL and low risk of psychosocial and 
physical long-term effects44,52,58. The HRQoL of endometrial cancer survivors 
approximates that of healthy controls within 3-5 years post-treatment44,51.  
 
Conflicting results have been found when addressing the effect on HRQoL of 
adjuvant radiotherapy. Here, Becker et al found that radiotherapy did not 
impact HRQoL or sexual function, while Lonneke et al showed that 
radiotherapy had a negative effect on HRQoL52,57. The latter was moreover 
the conclusion in a systematic Cochrane review of adjuvant radiotherapy for 
stage I endometrial cancer29. 
 
As obesity is a well-known risk factor for endometrial cancer, this could explain 
the high prevalence of obesity among endometrial cancer survivors59. When 
exploring the impact of physical activity and lifestyle on HRQoL, Basen-
Engquist et al and Gruenigen et al both concluded that the high prevalence of 
obesity and the associated poor lifestyle choices contributed significantly to 
the reduced quality of life found in these studies among endometrial cancer 
survivors49,50. 
 
In regard to surgical approach, Zullo et al examined HRQoL in a prospective 
randomized trial of open access surgery versus laparoscopic minimally 
invasive surgery48. Here, the authors found that patients treated with 
laparoscopic minimally invasive surgery scored significantly higher in HRQoL 
and lower in postoperative pain scores than those treated with open access 
surgery48. Similar conclusions were made by Kornblith et al in a HRQoL study 
of the Gynecologic Oncology Group Study LAP2 cohort, showing modest 




Of particular interest to the subject of this PhD dissertation, Salehi et al 
examined the HRQoL in the cohort defined by the RASHEC trial, mentioned 
above35,55. As the only published study of HRQoL among patients treated with 
robot-assisted minimally invasive surgery, the authors found no significant 
difference between HRQoL scores 12 months after RMIS compared to open 
access surgery for high-risk endometrial cancer with comprehensive 
lymphadenectomy55. 
 
In a recent study by Klapheke et al, prediagnose HRQoL scores were shown 
to be associated to the survival rate of elderly women with endometrial cancer, 
thus implying HRQoL to have a prognostic value in itself53. 
 
While generic HRQoL questionnaires, like SF-36 and QLQ-C30/EN24, are 
well-suited for a broad assessment of the quality of life, they are less suited 
for detailed assessments of chronic postoperative pain as these 
questionnaires only contain a limited number of items concerning pain45,46. 
Consequently, many studies of chronic postoperative pain utilize 
questionnaires developed specifically to address this subject61–65. 
Nonetheless, it is important to bear in mind that chronic postoperative pain is 
merely one aspect in the overall quality of life for the patients.  
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1.2. THE PHYSIOLOGY OF PAIN 
Knowledge of the basic principles of pain perception is essential when 
investigating the phenomenon of chronic postoperative pain. Therefore, a brief 
introduction to the relevant anatomy and physiology will be given in this 
section. 
 
1.2.1. THE DEFINITION OF PAIN 
The International Association for the Study of Pain (IASP) defines pain as  
“an unpleasant sensory and emotional experience associated with 
actual or potential tissue damage, or described in terms of such 
damage.” 66 
An unambiguous definition of chronic pain, nevertheless, has not been agreed 
upon. A widely used definition is persistent pain 3-6 months after the injury67. 
 
1.2.2. THE ASCENDING PATHWAY 
When tissue is exposed to 
a noxious stimulus, being 
mechanical, chemical or 
thermal, afferent sensory 
neurons are activated 
once a threshold is 
reached. The signal is 
passed along the axon of 
the neuron, termed the 
first-order neuron, to the 
root ganglia of the dorsal 
horn of the spinal cord68 
(fig. 4). 
Figure 4: Anatomy of the ascending pathway. Dorsal root ganglia 
(DRG), dorsal column (DC) and spinothalamic tract (STT), 
Secretory neuron (S), Motor neuron (M). 
Reprint from Wall and Melzack’s Textbook of Pain (p706), 
McMahon et al, 6th Edition, Elsevier, 2013. 
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Here it synapses with the second-order neuron which decussates to the 
contralateral side and ascends via the spinothalamic tract to the thalamus and 
synapses with the third-order neuron69. The nociceptive signals are processed 
in the brain stem, thalamus and the somatosensory cortex, where additional 
cognitive and emotional context may alter the perception of pain68. 
 
1.2.3. THE DESCENDING PATHWAY 
The existence of a descending 
modulatory control was proposed more 
than 50 years ago by Melzack and Wall, 
when they introduced the gate control 
theory70. The modulatory mechanism, 
which has since been shown to exist,  
describes how the dorsal spinal horn 
modulates neuronal activity by 
inhibiting or facilitating transmission of 
the impulses to the upper levels of the 
central nervous system71. Activity in the 
amygdala of the frontal lobe descends 
via neurons to the periaqueductal gray 
matter (PAG) located in the midbrain 
and then relays via synapses in the 
rostral ventromedial medulla (RVM). 
From here it descends further down the 
spinal cord and terminates in dorsal 
horn, where the release of neuro 
transmitters can inhibit or facilitate the 
transmission of signals from the 
afferent sensory nerves72 (fig. 5).  
 
Figure 5: Anatomy of the descending pathway.  
Periaqueductal gray matter (PAG), rostral 
ventromedial medulla (RVM), noradrenaline (NE), 
primary afferent nerve (P). Reprint from Wall and 
Melzack’s Textbook of Pain (p131), McMahon et al, 
6th Edition, Elsevier, 2013. 
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1.2.4. VISCERAL PAIN 
While pain arising from superficial somatic structures like skin, fascia or 
muscle is relatively well-described and studied, much less is known about 
visceral pain. Visceral structures are, in contrast to somatic structures, 
innervated by both spinal nerves (including sympathetic nerve fibers) and the 
parasympathetic vagus nerve and sacral nerves73. Furthermore, most visceral 
nerves synapse in pre- and paravertebral ganglia and give rise to secretory 
and motor neurons, thereby affecting the function of the organ (fig. 4)68.  
 
The afferent visceral nerves also synapse in the dorsal horn of the spinal cord, 
where they converge with nerve endings from other structures from the same 
spinal segment, i.e. somatic nerves from superficial structures or other 
visceral afferent nerves74. This anatomical relationship is the physiologic 
substrate for the phenomenon of referred pain between visceral structures 
and somatic structures (termed viscero-somatic convergence) or between two 
visceral structures (termed viscero-visceral convergence)67. An example of 
this phenomenon can be seen in cholecystolithiasis patients with cutaneous 
hyperalgesia in the referred area75,76. In contrast to somatic pain, visceral pain 
is often difficult to pinpoint and diffuse in character68. 
 
1.2.5. PRIMARY HYPERALGESIA 
Tissue injury induces a release of inflammatory mediators which lower the 
excitatory threshold of the afferent sensory nerves77. This sensitization 
process, termed primary hyperalgesia, increases the peripheral pain 
sensitivity temporarily and can be categorized as an adequate, physiologic 
response to trauma78. Once the noxious stimulus has stopped and the 
inflammation has subsided, the excitatory thresholds are - in most cases - 




1.2.6. CENTRAL SENSITIZATION 
The increase in sensory afferent neuronal activity during primary hyperalgesia 
causes an equivalent increase in the neuronal activity of the dorsal horn and 
the rest of the ascending pathway. In some cases, this central sensitization 
fails to diminish and can furthermore be accentuated by the loss of segmented 
inhibitory transmission79,80. This pathophysiologic phenomenon of widespread 
sensitization is believed to be a key element in chronic pain conditions with 
hyperalgesia and allodynia81. 
 
1.2.7. PRO- AND ANTINOCICEPTIVE MODULATORS 
A broad range of hormones and inflammatory mediators act as pro- or 
antinociceptive modulators, e.g. interleukin-1, interleukin-6 and tumor 
necrosis factor-α, adrenalin and noradrenalin77. Emerging evidence indicates 
that lipids and lipoproteins may also have a nociceptive modulatory effect via 
alterations of the cellular membrane microdomain composition82. Lipoproteins 
like the polyunsaturated fatty acids omega-3 and omega-6 demonstrate 
opposing effects on the serologic environment: The main omega-6 derivatives 
are linoleic acid (LA) and arachidonic acid (AA), both shown in studies to hold 
a pronociceptive capacity, while the omega-3 derivatives eicosapentaenoic 
acid (EPA) and docosahexaenoic acid (DHA) have an antinociceptive 
capacity83,84. 
 
The dietary intake of omega-6 and omega-3 fatty acids regulate the circulating 
levels as de novo synthesis in mammals is not possible85. An association 
between the dietary intake of fatty acids and nociception was shown in a study 
by Ramsden et al, where a diet induced reduction of circulating LA was shown 
to lower the frequency and severity of headaches among patients suffering 
from chronic headaches86.  Likewise, several rodent studies have shown a 




1.3. POSTOPERATIVE PAIN 
The terms persistent postsurgical pain, chronic postsurgical pain and chronic 
postoperative pain are often used interchangeably in the literature. 
Throughout this dissertation, only the term chronic postoperative pain will be 
used. 
 
Equivalent to a traumatic tissue injury, a surgical tissue injury triggers the 
same physiologic cascade of inflammation and neuronal sensitization77. 
Besides establishing a surgical access via the skin and connective tissue, the 
surgical procedure could moreover transect visceral nerves, e.g. in case of 
colectomy or hysterectomy, thus further increasing the synaptic activity and 
neuronal bombardment of the dorsal horn in the given spinal segment.  
 
Chronic postoperative pain is a severe clinical condition with disabling pain for 
1 out of 10 affected individuals89. Nevertheless, chronic postoperative pain 
has been largely unrecognized by clinicians77,90. In parallel, a review from 
2018 by Seers et al found that health care professionals underestimate the 
pain experienced by their patients and that the extent of underestimation 
tended to increase with pain severity91. 
 
The prevalence of chronic postoperative pain varies with the specific surgical 
procedure, e.g. 12.3% after caesarean section, 30.0% after hernia repair and 
52.6% after limb amputation92–94. Every year, 40 million patients in Europe and 
312 million patients worldwide undergo a surgical procedure95,96. Overall, an 
estimated 10% will develop a state of chronic postoperative pain, equivalent 
of more than 31 million new cases every year97. This alarming figure  
is gradually being recognized as a global public health problem, not only due 
to the significantly decreased quality of life of the affected individuals or the 
major socioeconomic burden it encompasses, but also due to the difficulties 




Many cases of chronic postoperative pain, including chronic postoperative 
pain following hysterectomy, exhibit the characteristics of neuropathic pain, 
e.g. burning pain with sensory loss and paradoxical hypersensitivity77,101. In 
these cases, sufficient analgesic effect can rarely be achieved by traditional 
first line drugs like acetaminophen and non-steroidal anti-inflammatory drugs, 
but require tricyclic antidepressants, serotonin norepinephrine reuptake 
inhibitors or gabapentanoids102.  
 
Opioids have traditionally also been prescribed as an integrated part of the 
pain management algorithm. The use of opioids for chronic pain conditions in 
general has increased vastly over the last three decades, especially in the 
USA, where nearly one-third of the adult population currently use prescription 
opioids103. From 1999 to 2014, death by drug overdose (mainly prescription 
opioids) tripled in the USA, prompting the US health municipalities to declare 
an ‘Opioid crisis’ and initiate programs in order to reduce the use / misuse of 
opioids104,105. 
 
1.3.1. FACTORS AFFECTING POSTOPERATIVE PAIN 
As described, the perception of pain can be modulated by a range of factors 
including neuronal sensitization, descending modulatory control and 
inflammatory mediators. Furthermore, numerous other factors have been 
shown to alter the perception of pain, including postoperative pain: 
 
Psychological factors 
The complex processing in the somatosensory cortex allows for pain 
perception to be altered by psychological conditions like pain catastrophizing, 
anxiety, depression, emotional distress and a history of sexual abuse106–111. 
This close relationship between psychological traits and perception of pain 
has been examined in a range of clinical studies, e.g. by Linton and Vlaeyen 
showing that the expectation of pain, fear and past memories all had a 
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negative effect on the perception of pain112,113. Conversely, cognitive therapy 
has been shown to modulate the perception of pain114. 
 
Socioeconomic factors 
Socioeconomic factors like low educational level, undesirable employment 
status and financial uncertainty have also been shown to have a negative 
effect on the experienced pain intensity and duration115–118. In a review from 
2008, Poleshuck and Green found that educational level was a good proxy 
for socioeconomic disadvantage as it was easy to obtain, unlikely to be 
changed by impaired health and had a better association with health status 
than income119. Additionally, socioeconomic disadvantage was consistently 
associated with increased morbidity, decreased life expectancy, higher infant 
mortality and increased risk for pain119,120. 
 
Comorbidity 
As described above, the central sensitization that occurs in chronic pain 
conditions may increase the perception of acute pain and the perpetuation to 
other forms of chronic pain121–123. Chronic pain is a common finding in patients 
with multimorbidity124,125. Consequently, this aspect may also affect the 
development of chronic postoperative pain. 
 
In a large cohort study of more than 200,000 people aged ≥65 years, Guisado-
Clavero et al found that multimorbidity clustered in patterns of musculoskeletal 
disease, endocrine-metabolic disease, digestive / digestive-respiratory 
disease, neurological disease and cardiovascular disease with a median 
number of diseases per capita of 7126. 
 
Barnett et al found that 23.0% of the examined patients in the primary care 
system had multimorbidity and that 46.0% of those with chronic pain had three 
or more disorders127. Furthermore, the prevalence of multimorbidity increases 






Some of the most frequent pain causing comorbidities include arthritis (which 
affects an estimated 68.7% of all women aged ≥65 years130); lower back pain 
(with a one-year prevalence of 38.0% in the adult population131); coronary 
heart disease (with a lifetime risk of 24.2% for women aged ≥70 years132) and 
diabetes mellitus (which affects 20.0% of all patients ≥65 years of age, while 
an estimated 51.0% of these patients will develop pain causing peripheral 
neuropathy133,134). 
 
Finally, multimorbidity has been associated with lower socioeconomic 
status135. Due to the association between multimorbidity and chronic pain, we 
must assume that a significant proportion of patients with endometrial cancer 
(incidence peak of 70-75 years of age) also have pain causing comorbidity. 
 
Figure 6: Number of chronic disorders by age-group. 
Reprint from Epidemiology of multimorbidity and implications for health care, research,  
and medical education: A cross-sectional study. Barnett et al.  




Lastly, we must assume that the development of chronic postoperative pain 
may be affected by any form of surgical complication or adjuvant treatment. 
For instance, surgical-site infection has been shown to increase the risk of 
postoperative pain and adjuvant chemotherapy with carboplatin / paclitaxel 
have been shown to hold a risk of polyneuropathy136–141. 
 
The use of analgesic medication pre- and postoperatively is also an important 
aspect for several reasons. Firstly, consumption of analgesics can serve as a 
surrogate marker of an underlying chronic pain condition. Secondly, prolonged 
opioid exposure in some individuals can trigger a paradoxical opioid-induced 
hyperalgesia with nociceptive sensitization, thus increasing the perception of 
pain142,143.   
 
For apparent reasons, any subsequent surgical procedure entails a de novo 
risk of postoperative pain development, thus obscuring if the primary or the 
secondary procedure initiated the postoperative pain - or if it was an additive, 
synergistic effect of both procedures. 
 
 
1.4. CHRONIC PAIN IN THE BACKGROUND POPULATION 
When studying the prevalence of chronic postoperative pain for a given 
surgical procedure, the expected prevalence of other underlying chronic pain 
conditions in the background population is an important aspect to take into 
consideration. In the case of endometrial cancer, the primary age group of 
interest is postmenopausal women aged 70 to 75 years. Ayorinde et al 
performed a cross-sectional study of 5,300 women in Scotland and found a 
prevalence of chronic pelvic pain of 7.4% in the age group 65-74 years and 
6.7% in the age group 75-84 years, while the prevalence was as high 
as 21.9% in the reproductive age groups144. The study further showed 
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that having multiple somatic symptoms was significantly associated with 
chronic pelvic pain in older women, thereby confirming the before mentioned 
association with multimorbidity144. An equivalent prevalence of chronic pelvic 
pain has been found in other studies by Ahangari et al, Zondervan et al and 
Mathias et al145–147. 
 
The prevalence of chronic pain (not only confined to pelvic pain) was 
examined by Dahlhamer et al in a large, population-based cross-sectional 
study in the USA148. Here the authors estimated that 20.4% of all adults had 
chronic pain and 8.0% had high-impact chronic pain. Additionally, the 
prevalence of both chronic pain and high-impact chronic pain were 




1.5. ASSESSMENT OF PAIN 
The subjective nature of pain entails an inherent challenge when trying to 
assess and quantify the painful experience. As a consequence, self-report has 
shown to be the most valid measure of pain68.  In the field of pain research, 
pain is often described by intensity, duration, location, and descriptive 
characteristics149. 
 
1.5.1. RATING SCALES 
A number of pain rating scales have been developed, where the Visual 
Analogue Scale (VAS) and the Numerical Rating Scale (NRS) are the most 
commonly used150. Using the VAS, the patient is asked to rate his/her pain on 
a 10 cm long scale from 0 cm meaning ‘No pain’ to 10 cm meaning ‘Maximum 
pain’151. With some resemblance, the NRS is a verbal or written 11 point scale 
from 0 meaning ‘No pain’ to 10 meaning ‘Worst possible pain’151.  Both VAS 
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and NRS has been shown to have high degrees of sensitivity as well as high 
degrees of test-retest reliability152–156. 
 
1.5.2. THE MEMORY OF PAIN 
The accuracy of recalled pain has been assessed in several studies. Erskine 
et al found a high degree of correlation between ratings of pain intensity while 
experiencing pain and the retrospective recalled rating157. Salovey et al 
studied the accuracy of self-reported pain intensity and found that not only 
was it accurate but also robust against the influence of transient moods158. In 
a study of recalled postoperative pain, Terry et al found that the intensity of 
pain was recalled accurately after six weeks - and to a higher degree than the 
quality of pain159. In a prospective study among fifty patients in the emergency 
room with acute pain, Singer et al examined the recalled pain intensity and 
correlation between the VAS and the NRS scale after one week and found 
that the patients accurately recalled the pain and that correlations between 
the scales ranged from 0.83 to 0.92160. 
 
In a large prospective study, Bąbel et al examined the accuracy of recalled 
pain among one hundred-and-forty women six months after gynecologic 
surgery, vaginal childbirth or caesarean section161. The authors concluded 
that the length of recall delay had no effect on memory of pain161. Similar 
conclusions were made by Cogan et al in a series of studies examining the  
reliability of a post-partum questionnaire where the patient reported pain 
measures were stable after one, three and six months162. 
 
Recently, Halicka et al published a well-designed study of the memory of 
postoperative pain in older patients undergoing hip surgery163. In accordance 
with the literature mentioned above, the authors found the recall of 
postoperative pain after three months to be accurate163.  
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1.6. QUANTITATIVE SENSORY TESTING 
Quantitative Sensory Testing 
(QST) has been used over the 
last 30 years as a non-invasive 
method to obtain an assessment 
of the psychophysical response 
to noxious stimuli, e.g. chemical, 
electrical, mechanical or thermal 
modalities164. QST has been 
proposed as a method to predict 
the outcome of surgery, i.e. 
predict pain reduction after 
surgery for chronic pain causing 
conditions or predict postoperative pain165,166. A short introduction will be given 
in this section, as several QST methods are evaluated in this PhD dissertation. 
 
1.6.1. PAIN THRESHOLDS 
Pain thresholds can be assessed by different methods, e.g. handheld 
algometry, cuff pressure algometry or thermal thresholds (fig. 7). Low pain 
thresholds suggest primary hyperalgesia when applied to a local painful 
location. In case of central sensitization, low pain thresholds at distal locations 
implies widespread hyperalgesia167. 
 
Pain thresholds have been studied extensively in various pain causing 
conditions, for instance in total knee replacement due to osteoarthritis, where 
low preoperative pain thresholds were associated with diminished 
postoperative pain relief168. In the field of gynecology,  reduced multifocal pain 
thresholds were found in patients with persistent pelvic pain169. 
 
Figure 7: Handheld algometer with a 1 cm2 probe 
which is placed perpendicular on the skin. 
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1.6.2. TEMPORAL SUMMATION OF PAIN 
Temporal summation of 
pain (TSP) occurs when 
repetition of a stimulus 
causes additive synaptic 
potentials in the neuron. 
This triggers a short-term 
sensitization of the spinal 
cord, which could lead to 
increased neuronal activity, 
thus allowing an otherwise 
painless stimulus to be 
perceived as painful170 (fig. 
8). A longer lasting sensiti-
zation of the spinal cord - which persists after the stimulus has ceased - has 
been shown in animal models171. This is termed wind-up and is believed to 
play an important role in human chronic pain conditions as well172.  
TSP is considered as a surrogate marker of central sensitization170 and has 
been utilized as a QST modality in multiple studies, for instance in a study of 
patients with overactive bladder syndrome where elevated levels of temporal 
summation were demonstrated. Furthermore, TSP has been shown to predict 
the level of postoperative pain after hip- and knee arthroplasty173,174. 
 
1.6.3. CONDITIONED PAIN MODULATION 
The phenomenon where a painful, noxious stimulus can alter the perception 
of another painful stimulus (“pain inhibits pain”) was first described by Le Bars 
et al in 1979175. In this study, where the activity of the dorsal horn neurons of 
rats were recorded during various noxious stimuli, a diffuse noxious inhibitory 
control (termed DNIC) was shown to inhibit 60-100% of the neuronal 
response, thereby serving as an endogenous analgesic system175. 
Figure 8: Temporal summation of pain. Visual Analogue 
Scale (VAS), Pain Threshold (PT).  
Reprint from Sensory assessment of regional analgesia in 
humans: a review of methods and applications. Curatolo 




An impaired or less efficient 
DNIC has since been shown in 
several idiopathic pain conditions 
like fibromyalgia and temporo-
mandibular disorder176,177. In a 
study published in 2008, 
Yarnitsky et al examined 62 
thoracotomy patients, aiming to 
determine if QST profiling of their 
DNIC could predict the degree of 
susceptibility to development of 
chronic post-operative pain166. 
The results showed that DNIC 
efficiency and the intensity of 
acute postoperative pain were 
both independent predictors of 
chronic postoperative pain166. Furthermore, a probability plot was constructed 
to visualize the relationship between the risk of chronic postoperative pain and 
DNIC efficiency on an arbitrary scale from -30 to 70 (fig. 9). The term 
conditioned pain modulation (CPM) has been used over the last decade to 
describe DNIC’s inhibitory effects in the descending pathway, especially in the 
setting of quantitative sensory testing, where it has been defined as the 
difference in the response to a painful stimulus applied before and during a 
painful conditioning stimulation178.  
 
Different CPM methods have been suggested over the course of time, many 
of which were found to have a lack of standardization and inherent observer 
bias issues179,180. As a consequence of these concerns, CPM assessment by 
cuff pressure algometry was developed as a user-independent method, which 
has been demonstrated to produce high levels of intraclass correlations in a 
study by Graven-Nielsen et al181. 
Figure 9: Logistic regression probability plot relating 
diffuse noxious inhibitory control (DNIC) to the 
probability of development of chronic pain. 
Reprint from Prediction of chronic post-operative 
pain: pre-operative DNIC testing identifies patients at 
risk. Yarnitsky et al. Aug. 2008. Pain. 138 (1): 22–8. 
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1.7. DEFINING THE KNOWLEDGE GAP 
As shown, endometrial cancer is a common malignant disease among 
postmenopausal women in the developed countries. Still, endometrial cancer 
has a very high survival rate and a low degree of postoperative sequelae 
through early diagnose and advanced surgical treatment. Like any other 
surgical procedure, however, hysterectomy entails a risk of developing chronic 
postoperative pain as an adverse outcome. Chronic postoperative pain 
decreases the quality of life for the affected individuals and poses a significant 
clinical challenge in the analgesic management as well as a major 
socioeconomic burden for the society. As robot-assisted laparoscopic 
hysterectomy for endometrial cancer is a fairly new surgical approach, the 
prevalence of chronic postoperative pain in this group of patients remains to 
be studied. As part of the evaluation of RMIS as a therapeutic intervention, 
this would allow for a direct comparison to the prevalences of chronic 
postoperative pain following hysterectomy by open access surgery or 
laparoscopic minimally invasive surgery found in previous studies. 
 
Chronic postoperative pain is the product of complex pathophysiologic 
interactions we do not fully understand. Some evidence suggest that a range 
of preoperative risk factors might increase the susceptibility to development of 
chronic postoperative pain, like pre-existing pain conditions or socioeconomic 
disadvantage. On a molecular level, emerging evidence also indicate that 
lipids, lipoproteins and other low-molecular metabolites can act as 
pronociceptive modulators, thus promoting the induction and perpetuation of 
chronic pain conditions. Therefore, a certain serologic composition could act 
as an independent risk factor for development of chronic postoperative pain. 
If we as clinicians knew some of these risk factors, we could counsel our 
patients better prior to surgery - and more importantly, possibly even find a 
way to reduce the risk of developing chronic postoperative pain through 
interventions and clinical trials. 
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Another approach to identify individuals with an increased susceptibility to 
development of chronic postoperative pain could be Quantitative Sensory 
Testing. Several studies have demonstrated the predictive capabilities of 
preoperative QST profiling, e.g. by identifying patients at risk of developing 
chronic postoperative pain after total knee replacement. Whether this also can 
be applied to robot-assisted laparoscopic hysterectomy for endometrial 
cancer has yet to be evaluated. If preoperative QST profiling could indeed 
identify patients at risk, we as clinicians could optimize the treatment 
algorithms in the pre- and postoperative setting through clinical trials, thereby 





CHAPTER 2. AIMS AND HYPOTHESES 
The overall aim of this PhD project was to investigate selected aspects of 
chronic postoperative pain after robot-assisted laparoscopic hysterectomy for 
endometrial cancer through three studies: 
 
2.1. STUDY I 
o Aim I: To determine the prevalence of chronic postoperative pain in a 
retrospective setting. 
 
o Aim II: To assess selected pre- and postoperative risk factors for 
development of chronic postoperative pain. 
 
o Hypothesis I: Development of chronic postoperative pain is 
associated to the pre- and postoperative risk factors: presence of 
preoperative pelvic pain, acute postoperative pelvic pain, age, 
severity of cancer, operating time, blood loss, educational level and 
employment status. 
 
2.2. STUDY II 
o Aim III: To investigate the serologic composition of lipids, lipoproteins 
and other low-molecular metabolites in preoperative blood samples 
from patients with chronic postoperative pain. 
 
o Hypothesis II: Patients who develop chronic postoperative pain have 
a distinctive preoperative serologic composition of lipids, lipoproteins 
and other low-molecular metabolites, compared to patients who do 




o Aim IV: To explore if serological biomarkers are predictive for 
development of chronic postoperative pain. 
 
o Hypothesis III: Serologic biomarkers of lipids, lipoproteins and other 




2.3. STUDY III 
o Aim V: To determine the prevalence of chronic postoperative pain in 
a prospective setting. 
 
o Aim VI: To assess selected preoperative risk factors for development 
of chronic postoperative pain. 
 
o Hypothesis IV: Development of chronic postoperative pain is 
associated to the preoperative risk factors: presence of preoperative 
pelvic pain, age, severity of cancer, educational level and employment 
status. 
 
o Aim VII: To evaluate if preoperative profiling by quantitative sensory 
testing can predict chronic postoperative pain. 
 
o Hypothesis V: Quantitative sensory testing by handheld algometry, 
cuff pressure algometry, temporal summation of pain, conditioned 
pain modulation and heat evoked pain can predict development of 





CHAPTER 3. MATERIALS AND 
METHODS 
3.1. GENERAL STUDY POPULATION 
All three studies were conducted at The Department of Obstetrics and 
Gynecology, Aalborg University Hospital, Denmark. The general inclusion 
criteria were women diagnosed with endometrial cancer, scheduled for robot-
assisted laparoscopic hysterectomy and bilateral salpingo-oophorectomy, 
aged 18 to 85 years-of-age. The general exclusion criteria were non-Danish 
speaking, use of cannabis or opioids, conversion to laparotomy during the 
surgical procedure or subsequent laparotomy, neurologic-, musculoskeletal- 
or mental illnesses1–3. 
 
All participants were given written and verbal information and signed informed 
consent forms prior to inclusion. The studies were approved by The North 
Denmark Region Committee on Health Research Ethics (N-20150028), The 
Danish Data Protection Agency (2008-58-0028) and The Bio- and Genome 
Bank Denmark1–3. 
 
3.2. STUDY DESIGNS AND PARTICIPANTS 
3.2.1. STUDY I 
Study I was a questionnaire survey among patients treated from January 1st, 
2010 till July 31st, 2015. To address the aims and hypothesis, the design 
consisted of two parts where the first part was a cross-sectional assessment 
of the prevalence of chronic postoperative pain, while the second part was a 
cohort study with retrospective assessment of risk factors for development of 





3.2.2. STUDY II 
A nested, case-control study within the cohort defined by Study I. 
 
3.2.3. STUDY III 
A longitudinal, observational cohort study of patients treated from August 1st, 
2015 till December 31st, 2018. 
 
3.3. MEASURING CHRONIC POSTOPERATIVE PAIN 
To determine the outcome measure, the presence of chronic postoperative 
pain, we decided to use a questionnaire approach. The questionnaire should 
address the presence, location and intensity of pain in a range of everyday 
activities and consist of two parts regarding the preoperative- and the 
postoperative time period, respectively. Preferably, this questionnaire should 
be thoroughly validated and in Danish language. Finally, the questionnaire 
should be developed for use in our primary study population of 
postmenopausal women undergoing a hysterectomy. 
 
Despite a systematic literature search on the topic, we were unable to find a 
questionnaire meeting all of the above requirements. In the light of these 
findings, we decided to use a questionnaire concerning chronic postoperative 
pain following hysterectomy developed by Birgitte Brandsborg and colleagues 
at The Danish Pain Research Center, Aarhus University.  The questionnaire 
was originally developed as a part of a PhD project concerning chronic 
postoperative pain after hysterectomy on benign indication182. 
 
Brandsborg’s questionnaire utilized the general terminology and systematics 
of the validated Brief Pain Inventory questionnaire but also contained more 
specific items related to hysterectomy183,184. The questionnaire consisted of 
47 items in Danish language. It was pilot tested on 20 patients who had 
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previously undergone a hysterectomy, identified via The Danish Hysterectomy 
Database. Based on the response, the questionnaire was adjusted and a final 
version of the questionnaire was utilized in the further studies61,185. 
 
For the present PhD project, the original questionnaire by Brandsborg was 
slightly modified at Center for Sensory-Motor Interaction, Center for 
Neuroplasticity and Pain, Aalborg University: The number of items was 
reduced to 32 as e.g. questions using McGill pain descriptors were removed. 
This was done to have as few items as possible while still allowing for an 
assessment of the construct186,187. Furthermore, the questions regarding the 
duration of pain were changed from ‘three months’ to ‘six months’ as a 
consequence of the definition of chronic postoperative pain applied in this PhD 
project. 
 
The modified questionnaire was then controlled for face validity, which is 
defined as the degree to which the respondent understands the questions and 
find them relevant188.  This was done among 10 patients who had been treated 
for endometrial cancer 2-3 years prior with robot-assisted hysterectomy at The 
Department of Obstetrics and Gynecology, Aalborg University Hospital. These 
patients matched the study population of interest and were subsequently 
excluded from Study I. After returning the filled-out questionnaires, each 
responder was interviewed by verbal probing technique by telephone 
regarding each item to ensure that the questions had been perceived as clear 
and unambiguous189. Content validity is defined as the degree to which a 
panel of experts find the items representative of the theoretical construct190. 
This was controlled by review of the questionnaire by pain researchers from 
Center for Sensory-Motor Interaction, Center for Neuroplasticity and Pain, 
Aalborg University as well as clinicians from The Department of Obstetrics 
and Gynecology, Aalborg University Hospital, thereby allowing for experts on 
both pain research and endometrial cancer to comment on the questionnaire. 
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Further theoretical aspects of questionnaire validation are discussed in detail 
in section ‘5.6. Methodological Considerations’. 
 
The following variables were collected: presence of preoperative pelvic pain, 
acute postoperative pelvic pain, chronic postoperative pelvic pain, pain 
intensity ratings, frequency and location of the pain (marked on an illustration 
of a woman’s torso), and lastly demographic data such as educational level 
and employment status1,3.  
 
Throughout Study I-III, the definition of chronic postoperative pain was 
persistent, moderate to severe pain on a daily basis with a mean VAS ≥ 3, six 
months after the surgical procedurea, based on the answers of question 
number 9A, 9B, 9D and 10A. Please refer to the original Danish questionnaire 
in appendices or the translated questionnaire in Paper III. 
 
3.3.1. STUDY I 
Study participants were identified via the database of The Department of 
Obstetrics and Gynecology, Aalborg University Hospital of patients treated 
from January 1st, 2010 till July 31st, 2015. 
 
The questionnaire was mailed along with a prepaid return envelope to each 
participant. Non-responsive participants were contacted by telephone 3 
weeks after receiving the mailed questionnaire and again after 2 weeks, if the 
participant did not respond. The returned questionnaires were gathered for 
data analysis1.  
 
 
a Erratum: Paper I incorrectly states that chronic postoperative pain was defined as  
  “constant or periodical pain for at least 3 months”, while the definition is specified   
   correctly in Paper II and III. 
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3.3.2. STUDY II 
The questionnaire was indirectly utilized in Study II, being a nested, case-
control study within the cohort defined by Study I. 
 
3.3.3. STUDY III 
In this study, the questionnaire was primarily applied to obtain an estimate of 
postoperative pain as an outcome measure. Furthermore, the questionnaire 
allowed for profiling of the preoperative pain status of the participants. 
 
Study participants were consecutively included prior to the surgical procedure 
from August 1st, 2015 till December 31st, 2018. The questionnaire was mailed 
along with a prepaid return envelope to each participant six months after the 
surgical procedure and non-responsive participants were contacted by 
telephone after the same algorithm as in Study I. The returned questionnaires 
were gathered for data analysis3. 
 
 
3.4. REVIEW OF THE MEDICAL RECORDS  
The medical records of all study participants (Study I-III) were reviewed for 
details concerning Body Mass Index (BMI) at the time of surgery (kg/m2), 
duration of surgery (minutes), the blood loss during surgery (mL), 
intraoperative lesions if any, postoperative complications if any, parity, number 
of caesarean sections if any, and histopathologic diagnose and stage of 
cancer.  
 
The review of medical records furthermore disclosed if any exclusion criteria 





3.5. METABOLIC PROFILING 
In Study II we performed metabolic profiling of cases with chronic 
postoperative pain compared with controls without chronic postoperative pain, 
in order to examine the serologic composition of lipids, lipoproteins and other 
low-molecular metabolites.  
 
3.5.1. THE DANISH CANCER BIOBANK 
Since 2009, all cancer patients in Denmark have been offered to have blood 
and tissue samples stored in The Danish Cancer Biobank (DCB), part of a 
national collaboration between public hospitals entitled The Bio- and Genome 
Bank Denmark. Following an informed consent, the biologic materials are 
stored according to the Danish Data Protection Agency procedures2.  
 
The majority of the study participants had blood and tissue stored in the DCB, 
and the fact that the blood samples were drawn preoperatively, allowed us to 
perform an assessment of the preoperative serologic composition. 
 
The cases with chronic postoperative pain were matched on age and BMI in 
a 1:2 ratio with controls without chronic postoperative pain from the cohort2. 
 
3.5.2. THE NMR SPECTROSCOPY 
Any type of biochemical com-pound consist of atoms in which the different 
nuclei have an intrinsic angular momentum or gyromagnetic spin (fig. 10)191.  
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The spin is highly dependent on 
the number of unpaired protons 
and neutrons in the nucleus as 
well as the chemical surround-
dings. In NMR spectroscopy, 
compounds are placed in a 
magnetic field and radiated with 
electromagnetic waves at specific 
wavelengths for each element and 
isotope192. When the electro-
magnetic waves are exactly the 
same as the precessional frequency of the spin (termed the Lamor frequency), 
the nucleus is excited and briefly transition to a different state of spin191. 
Shortly after, the nucleus will return to the ground spin state and emit an 
electromagnetic wave at the same resonance frequency. When performing 
NMR spectroscopy of a biochemical compound, numerous electromagnetic 
waves are emitted at different frequencies which allows for identification of the 
various elements as ‘molecular finger-prints’. The technology of high-
throughput NMR spectroscopy has advanced immensely in the recent years, 
thus for allowing for detailed metabolic profiling193. 
 
The metabolic profiling in Study II was performed by means of serum analysis 
on a high-throughput NMR metabolomics platform (Nightingale Health Ltd., 
Helsinki, Finland), which provided quantification of routine lipids and 
lipoproteins, fatty acids and various low-molecular metabolites, including 
amino acids, ketone bodies, and gluconeogenesis-related metabolites2,193. 
 
 
Figure 10: Nucleus with precessional spin in a 
magnetic field. 
Reprint from Libretexts Chemistry. Thomas 
Wenzel. Open access via Creative Commons 




3.6. QUANTITATIVE SENSORY TESTING  
All study participants in Study III were included consecutively and subjected 
to a test platform of selected QST modalities 2-3 days prior to the surgical 
procedure. All participant information and testing was performed by one 
examiner (Søren Lunde)3.  
 
The QST modalities are described in detail in Paper III and will be summarized 
below. 
 
3.6.1. HANDHELD ALGOMETRY  
A handheld algometer (Somedic AB, Hörby, Sweden) (fig. 7) with a 1 cm2 
probe was placed perpendicular on the skin. Pressure was applied and 
increased gradually until the Pressure Pain Threshold (defined as ‘‘the point 
at which the pressure sensation becomes painful”) (PPT) was reached. The 
PPT was assessed at 8 different landmark locations on the body, 4 on each 
side (lower back, legs and arms)3. 
 
3.6.2. CUFF PRESSURE ALGOMETRY  
Deep-tissue pain sensitivity was assessed by cuff pressure algometry in which 
a double-chamber tourniquet cuff (VBM Medizintechnik GmbH, Sulz, 
Germany) was placed on the right lower leg. The cuff was connected to a 
computer-controlled compressor and a 10 cm long, electronic Visual Analogue 
Scale (VAS) from 0 cm to 10 cm (Cortex Technology and Aalborg University, 
Aalborg, Denmark). The cuff was inflated at 1 kPa/s and the pain intensity 
during inflation of the cuff was recorded via the electronic VAS. The VAS 0 cm 
and 10 cm extremes on the VAS were defined as “no pain” and as “maximum 
pain”, respectively. The patient was instructed to rate the pain intensity 
continuously on the VAS from the first sensation of pain until the pain intensity 
was so high, that she wanted to terminate the test (Pain Tolerance Threshold, 
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PTT). The Pain Detection Threshold (PDT) was defined as the pressure at 
which VAS had exceeded a score of 23.  
 
3.6.3. TEMPORAL SUMMATION OF PAIN  
The cuff pressure algometry device was further utilized to assess the TSP. 
The average of the previously obtained PDT and PTT levels was automatically 
calculated, and the cuff was now inflated to this pressure in a series of 10 
stimuli at 0.5 Hz. During the series of stimuli, the patient was instructed to rate 
the pain intensity on the electronic VAS. The mean VAS during stimuli number 
1-3 (VAS-I) and stimuli number 8-10 (VAS-III) was calculated and TSP was 
defined as the difference between the first and the last mean values (VAS-III 
minus VAS-I)3,168,194. 
  
3.6.4. CONDITIONED PAIN MODULATION  
A second, double-chamber tourniquet cuff (VBM Medizintechnik GmbH, Sulz, 
Germany) connected to the cuff pressure algometry device was placed on the 
left lower leg and  a painful conditioned stimulus was administered via inflation 
to the level of 70% of the PTT181. Simultaneously, on the right lower leg, the 
first cuff was inflated by increasing pressure. The patient was instructed to 
rate the pain intensity via the electronic VAS and exclusively focus on the pain 
evoked by the cuff on the right leg and disregard the pain evoked by the cuff 
on the left leg. The Conditioned Pain Modulation (CPM) was defined as the 
difference between PDT with and without the conditioning stimulus3.  
 
3.6.5. HEAT EVOKED PAIN  
Thermal stimulation was applied by placing a 3×3 cm contact thermode 
(Medoc Advanced Medical Systems, Ramat Yishai, Israel) on an area of skin 
on the lower back between the L2 and the L4 vertebra. Each stimulus was 
started with a thermode temperature of 32°C and tests were performed by 
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raising the temperature by 0.5°C/s3,195,196. The patient was instructed to press 
a button when she perceived the stimulation as warm (Warm Detection 
Threshold, WDT) and press the button again once the heat stimulation was 
perceived as pain (Heat Pain Threshold, HPT)3. 
 
 
3.7. THE SURGICAL PROCEDURE 
All surgical procedures in Study I-III were performed at Aalborg University 
Hospital using Da VinciTM Si robotic systems (Intuitive Surgical Inc., 
Sunnyvale, USA). 
 
During Study I (and II), lymphadenectomy was performed according to the 
ESMO-ESGO-ESTRO guideline based on the preoperative histopathologic 
diagnosis and an intraoperative macroscopic assessment of the tumor’s 
myometrial invasion by a trained pathologist. In the summer of 2015, however, 
Aalborg University Hospital adopted the Memorial Sloan Kettering Cancer 
Center Sentinel Lymph Node algorithm (as described in section 1.1.4). 
Consequently, this approach was applied in Study III. 
 













3.7.1. PERI- AND POSTOPERATIVE DRUG DOSE REGIMEN 
All participants in Study I-III were treated with a uniform drug dose regimen: 
 
o 30 minutes prior to the surgical procedure, a dose of Gabapentin (300 
mg p.o.) was administered. 
 
o Total intravenous anaesthesia was obtained with a combination of 
Propofol (10 mg/kg/hour i.v.) and Remifentanil (1 μg/kg/minute i.v.) 
and non-depolarizing neuromuscular blockade by Mivacurium 
chloride (0.2 mg/kg/hour i.v.). 
 
o Cefuroxime (1,500 mg i.v.) and Metronidazole (1,000 mg i.v.) were 
given as prophylactic antibiotics and Tranexamic acid (1,000 mg i.v.) 
as prophylactic haemostatic. 
 
o In order to reduce the level of postoperative nausea and vomiting, 
Dexamethasone (8 mg i.v.) and Ondansetron (4 mg i.v.) were 
administered during the surgical procedure. 
 
o In the postoperative setting, analgesic management consisted of 
Paracetamol (1,000 mg x 4 p.o.) and Naproxen (500 mg x 2, p.o.) for 
two weeks while Dalteparin (5,000 IU s.c.) was given as thrombosis 






3.8. STATISTICAL ANALYSIS  
Chronic postoperative pain was defined as persistent, moderate to severe 
pain on a daily basis with a mean VAS ≥ 3 six months after the surgical 
procedure. The assumptions behind the statistical tests were assessed prior 
to analysis, including the distributions of variables. P ≤ 0.05 was considered 
statistically significant. 
 
3.8.1. STUDY I 
Continuous data were displayed as mean with 95% confidence intervals (CI) 
and categorical data were displayed as frequency in percentage1. 
 
To examine potential selection bias among questionnaire responders and 
non-responders, a Mann-Whitney–U test of the two groups were performed 
using the independent variables age, BMI, operating time and blood loss1. 
 
Hypothesis Ib was tested by a binary logistic regression analysis with 
backward stepwise selection of risk factors for chronic postoperative pain with 
the following independent variables: preoperative pelvic pain; acute 
postoperative pain intensity; preoperative pain elsewhere; age; stage of 
cancer; operating time; blood loss; education; and employment status1. 
 
The statistical analyses were performed with IBM SPSS Statistics software for 
Mac OS, Version 25.0 (IBM Corp., Armonk, NY).  
 
 
b Hypothesis I: Development of chronic postoperative pain is associated to the pre- 
and postoperative risk factors: presence of preoperative pelvic pain, acute 
postoperative pelvic pain, age, severity of cancer, operating time, blood loss, 
educational level and employment status. (Section 2.1.). 
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3.8.2. STUDY II 
In order to investigate any inherent clustering in the data and reduce possible 
overfitting and noise, the entire dataset was pre-processed by Principal 
Component Analysis (PCA), thereby reducing the dimensionality and the 
number of variables of the data, while still maintaining as much variance as 
possible (fig. 11)2,197. 
  
 
Hypothesis IIc was tested by the subsequent supervised modelling by a sparse 
Partial Least Squares-Discriminant Analysis (sPLS-DA) as described by Lê 
Cao et al198, thus effectively reducing the number of variables in high-
dimensional metabolomics data further2.  
 
 
c Hypothesis II: Patients who develop chronic postoperative pain have a distinctive 
preoperative serologic composition of lipids, lipoproteins and other low-molecular 
metabolites, compared to patients who do not develop chronic postoperative pain. 
(Section 2.2.). 
Figure 11: Principal component analysis (PCA) reduces a large number of variables (in this 
example gene expression) to a lower number of new variables termed principal components 
(PCs). Three-dimensional gene expressions are projected onto a two-dimensional component 
space that maintains the largest variance in the data. 
Reprint from Approaches to analyse and interpret biological profile data, PhD dissertation by 





For evaluation of the classification performance, 5-fold cross-validation 
together with the receiver operating characteristic curve (ROC) was chosen. 
Additionally, four machine learning algorithms (random forest, linear support 
vector machine, PLS-DA and logistic regression) were applied to develop 
prediction models for chronic postoperative pain based on the identified 
metabolomic biomarkers, thus testing hypothesis IIId. Finally, a permutation 
test was used to indicate whether the specific classification model was 
superior to random classifiers2.  
 
All multivariate statistics, including unsupervised PCA and supervised sPLS-
DA, were performed using MetaboAnalystR 2.0 packages2,199. 
 
 
3.8.3. STUDY III 
All study parameters were analysed with independent samples t-test between 
the two sub-groups with and without chronic postoperative pain, thereby 
testing hypothesis IVe. Results were displayed as mean and standard 
deviation (SD) for continuous variables - except results from the Thermal 
Stimulation which were displayed as Mean, Quartiles and Range - and as 
proportions with corresponding frequencies for categorical variables3.  
 
A responder versus non-responder analysis was performed in order to 
examine potential selection bias, similar to Study I. Finally, a binary logistic 
 
d Hypothesis III: Serologic biomarkers of lipids, lipoproteins and other low-molecular 
metabolites are predictive for development of chronic postoperative pain. (Section 
2.2.). 
e Hypothesis IV: Development of chronic postoperative pain is associated to the 
preoperative risk factors: presence of preoperative pelvic pain, age, severity of cancer, 
educational level and employment status. (Section 2.3.). 
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regression model was established using the statistically significant 
preoperative parameters, thereby testing hypothesis Vf. 
 
The statistical analysis was performed using IBM SPSS Statistics software for 








f Hypothesis V: Quantitative sensory testing by handheld algometry, cuff pressure 
algometry, temporal summation of pain, conditioned pain modulation and heat evoked 






CHAPTER 4. RESULTS 
The main results of Study I-III are summarized below, whereas the complete 
results are described in greater detail in the Paper I-III (see appendices). 
 
4.1. STUDY I 
Two-hundred-and-eighty patients were treated for endometrial cancer at 
Aalborg University Hospital in the time period from January 1st, 2010 till July 
31st, 2015. Eight patients were excluded due to dementia, subsequent open 
surgery or death. The remaining two-hundred-and-seventy-two were included 
in the study and received the questionnaire via mail. Two-hundred-and-seven 
patients returned the questionnaire (76.1%) whereas sixty-five patients did not 
return the questionnaire within 5 weeks (23.9%) (fig. 12)1.  
 
Figure 12: Flowchart of Study I. 
Reprint from Chronic Postoperative Pain after Robot-Assisted Laparoscopic Hysterectomy for 





4.1.1. NON-RESPONDER ANALYSIS 
The mean age of the non-responders was significantly lower compared to the 
responders (63.4 years, 95% CI 60.6-65.7 versus 67.2 years, 95% CI 65.9-
68.5, p = 0.027), no difference was found in BMI (p = 0.869), duration of 
surgery (p = 0.551) or blood loss (p = 0.126)1. See section 4.1.4. for a 
supplemental sensitivity analysis regarding the non-responders. 
 
4.1.2. BASELINE CHARACTERISTICS 
The baseline characteristics of the responders are shown in table 2. 
  
Baseline characteristics (n = 207)   Mean (CI)a 
Age, years 67.2 (65.9-68.5) 
BMIb, kg/m2 29.4 (28.5-30.3) 
Operating time, minutes 
Blood loss during surgery, mL 
Follow-up time since surgery, days 
      






 Elementary school 
High school 
Vocational school  














Employment status  
Full time 
Part time 




























Table 2: Baseline characteristics. aData displayed as Mean (95% Confidence Interval, CI) for 
continuous data and n (%) for categorical data.bBody Mass Index. 
Reprint from Chronic Postoperative Pain after Robot-Assisted Laparoscopic Hysterectomy for 





4.1.3. TUMOR CHARACTERISTICS 
The tumor characteristics of the responders are shown in table 3. 
  
 
4.1.4. PAIN CHARACTERISTICS 
A total of thirty-one out of the two-hundred-and-seven responders had chronic 
postoperative pain, equivalent to a prevalence of 14.9% (95% CI 10.4-20.6).  
 
Tumor characteristics (n = 207)         n (%)  
Histologic type and grade  
    Endometrioid carcinomas 
 
          Endometrioid adenocarcinomas            183 (88.4) 
                Grade 1 
                Grade 2 
                Grade 3 
    Non-endometrioid carcinomas   
          Serous adenocarcinomas                                   
          Clear cell adenocarcinomas  
          Carcinosarcomas                
    Sarcomas 
          Adenosarcomas 
 
FIGOa stage 
    IA 
    IB 
    II 
    III 
    IV 
 
Risk categories 
    Low risk 
          Stage IA (grade 1-2) with endometrioid type 
    Intermediate risk 
           Stage IA (grade 3) with endometrioid type 
           Stage IB (grade 1-2) with endometrioid type 
    High risk 
            Stage IB (grade 3) with endometrioid type 
            Stage II with endometrioid type 
            Stage III with endometrioid type 
            All non-endometrioid types incl. sarcomas 
                                       145 (70.0)  
  32 (15.5) 
   6 (2.9) 
                                23 (11.1)  
           15 (7.2)                                                                       
2 (1.0) 
     6 (2.9) 
1 (0.5) 



















24 (11.6)                
  
Table 3: Tumor characteristics. Data displayed as n (%). aFédération Internationale de 
Gynécologie et d’Obstétrique. 
Reprint from Chronic Postoperative Pain after Robot-Assisted Laparoscopic Hysterectomy for 





If we were to estimate the true prevalence of chronic postoperative pain in the 
entire study sample of two-hundred-and-seventy-two participants, we could 
conduct a hypothetical sensitivity analysis. Had the sixty-five non-responders 
indeed responded, we could calculate two extreme scenarios where these 
non-responders had a) half the prevalence or b) twice the prevalence of the 
responder-group200. This yielded a prevalence of chronic postoperative pain 
between a) 13.2% (95% CI 9.4-17.8) to b) 18.8% (95% CI 14.3-23.9) in the 
entire study sample, respectively. 
 
The pain characteristics of the responders are shown in table 4. 
  
Pain characteristics Preoperative pain, 
n(%)a 
Postoperative chronic pain, 
n(%)a 
Total (n = 207)  35 (16.9) 31 (14.9) 
Age   
 Age ≤ 67 years (n = 111)b 25 (22.5) 24 (21.6) 
 Age > 67 years (n = 96) 10 (10.8) 7 (7.3) 
BMIc, kg/m2   
 BMI ≤ 29 (n = 109)d 18 (16.5) 16 (14.7) 
 BMI > 29 (n = 98) 17 (17.3) 15 (15.3) 
Pain frequency (n = 35/31)   
 1-3 days/week 16 (45.7) 16 (51.6) 
 4-6 days/week 4 (11.4) 2 (6.5) 
 Every day 15 (42.9)   12 (38.7)   
Pain during factors (n = 35/31)   
 Running 6 (17.1)   8 (25.8)  
 Wearing tight clothes 8 (22.9)  6 (19.4)  
 Having sexual intercourse  13 (37.1) 9 (29.0)  
 Carrying heavy things  14 (40.0)  15 (48.4) 
 Other situations 9 (25.7) 15 (48.4) 
Affected Sex life (n = 14/10) 7 (50.0) 5 (50.0) 
Affected Sleep (n = 35/31)  12 (34.3) 14 (45.2)  
Pain elsewhere (n = 35/31)  9 (25.7) 15 (48.4) 
Caesarean Section (n = 35/31) 
 







Postoperative chronic pain, 
mean (CI)a   
     Daily 4.3 (3.2-4.8) 3.6 (2.8-4.4) 
     At worst 5.6 (4.6-6.5) 5.7 (4.8-6.7) 
 
Table 4: Pain characteristics of the preoperative pelvic pain and postoperative pelvic pain. aData 
displayed as n (%) for categorical data and Mean (95% Confidence Interval, CI) for continuous 
data. bBased on the mean age of the study sample. cBody Mass Index. dBased on the mean BMI 
of the study sample. eIntensity ratings by Numeric Rating Scale (NRS). 
Reprint from Chronic Postoperative Pain after Robot-Assisted Laparoscopic Hysterectomy for 





As supplemental material to Paper I, tables 5 and 6 were constructed to 
visualize the degree of overlap between patients with pre- and postoperative 
pain. 
  
    Postoperative pain Total 
      + -   
Preoperative pain  + 16 19 35 
  - 15 157 172 
Total   31 176 207 
  
As shown in table 5, sixteen out of thirty-one patients with postoperative pain 
indicated an existing preoperative pain condition, equivalent of 51.6% (95% 
CI 33.1-69.8). 
 
Preoperative pain Postoperative pain n  % 95% CI 
- - 157 75.8 69.4-81.5 
- + 15 7.3 4.1-11.7 
+ - 19 9.2 5.6-14.0 
+ + 16 7.7 4.5-12.2 
Total  207 100.0  
 
As table 6 shows, 75.8% of the responders had neither pre- nor postoperative 
pain, while the remaining 24.2% were evenly distributed in three diminutive 
groups with combinations of pre- and postoperative pain, demonstrating no 
significant difference between groups. 
 
The thirty-one patients with chronic postoperative pain had marked the areas 
of pain on the illustration of a woman’s torso in their questionnaire response.  
A graphical summation of these areas was constructed on the basis of the 
questionnaires (fig. 13).  
Table 5: Cross tabulation of the variables pre- and postoperative pain among patients.  
Data displayed as n, stratified into the respective groups. 
 
Table 6: Frequency distribution of the variables pre- and postoperative pain among patients.  





4.1.5. THE BINARY LOGISTIC REGRESSION MODEL 
A binary logistic regression model was built, initially using nine variables 
(model 1) with a subsequent backward stepwise selection, reducing the 
number of variables to four (model 2) (table 7). The unadjusted odds ratio for 
the variable ‘preoperative pelvic pain’ was 8.81 (95% CI 3.43-22.38). 
  
Model 1                                                                                                       Nagelkerke R2  0.419                                                                                                                                                     
Variable OR (CI)a p-value 
Preoperative pelvic pain   4.24 (3.34-5.14) 0.002 
Acute postoperative pain 1.20 (1.00-1.40) 0.067 
Preoperative pain elsewhere 2.66 (1.52-3.80) 0.092 
Age 
Severity of Cancer 
Operating time  















    
Model 2                                                                                                       Nagelkerke R2  0.382 
Variable OR (CI) p-value 
Preoperative pelvic pain   4.99 (4.15-5.83) 0.000 







Table 7: Binary logistic regression with backward stepwise selection of risk factors for 
postoperative chronic pain following robot-assisted hysterectomy. a Data displayed as Odds Ratio 
(95% Confidence Interval, CI). 
Reprint from Chronic Postoperative Pain after Robot-Assisted Laparoscopic Hysterectomy for 
Endometrial Cancer. Lunde et al. Journal of Gynecologic Surgery. Volume 35, Issue 3, June 2019, 
140-146. 
 
Figure 13: Summarized 
areas of chronic 
postoperative pain based on 
thirty-one questionnaire 
responses. 
Reprint from Chronic 
Postoperative Pain after 
Robot-Assisted Laparoscopic 
Hysterectomy for 
Endometrial Cancer.  
Lunde et al. Journal of 
Gynecologic Surgery. 




4.2. STUDY II 
In the cohort defined by Study I, thirty-one patients with chronic postoperative 
pain and one-hundred-and-seventy-six patients without chronic postoperative 
pain were identified (fig. 14). 
 
  
Figure 14: Flowchart of Study II. 
Reprint from Chronic Postoperative Pain After Hysterectomy for Endometrial Cancer: A Metabolic 




Twenty-six of the thirty-one patients with chronic postoperative pain had 
preoperative blood samples stored in The Danish Cancer Biobank (DCB). 
These twenty-six cases were matched on age and BMI in a 1:2 ratio with fifty-
two controls without chronic postoperative pain, who also had preoperative 
blood samples stored in the DCB (fig. 14)2. 
 
4.2.1. TUMOR CHARACTERISTICS 
As supplemental material to Paper II, table 8 shows the tumor characteristics 
of the seventy-eight total cases and controls. 
 
Tumor characteristics (n = 78)         n (%)  
Histologic type and grade  
    Endometrioid carcinomas 
 
          Endometrioid adenocarcinomas            68 (87.2) 
                Grade 1 
                Grade 2 
                Grade 3 
    Non-endometrioid carcinomas   
          Serous adenocarcinomas                                   
          Clear cell adenocarcinomas  
          Carcinosarcomas                
    Sarcomas 
          Adenosarcomas 
 
FIGOa stage 
    IA 
    IB 
    II 
    III 
    IV 
 
Risk categories 
    Low risk 
          Stage IA (grade 1-2) with endometrioid type 
    Intermediate risk 
           Stage IA (grade 3) with endometrioid type 
           Stage IB (grade 1-2) with endometrioid type 
    High risk 
            Stage IB (grade 3) with endometrioid type 
            Stage II with endometrioid type 
            Stage III with endometrioid type 
            All non-endometrioid types incl. sarcomas 
                                         54 (69.2) 
  14 (18.0) 
   0 (0.0) 
                                10 (12.8)  
           6 (7.7)                                                                       
1 (1.3) 
     2 (2.6) 
1 (1.3) 



















10 (12.8)                
  
Table 8: Tumor characteristics. Data displayed as n (%). aFédération Internationale de 





4.2.2. METABOLIC PROFILE VARIANCE 
To compare the overall variation of metabolic profiles between the cases and 
controls, a classification model was built by supervised sPLS-DA. This sPLS-
DA model, however, did not show separation between the two groups (fig. 15, 
a) and the calculated validation parameters had low values (data not shown)2. 
 
Of the seventy-eight total cases and controls in this study, fifty-nine patients 
were classified accordingly to the ESMO-ESGO-ESTRO guidelines as low or 
intermediate-risk and nineteen patients as high-risk (table 8).  
 
As the biological etiology of type II tumors differ to a large extent from type I 
tumors, the high-risk cases were excluded in a second sPLS-DA model as 
more than half of the high-risk cases consisted of non-endometrioid 
carcinomas. Therefore, this second sPLS-DA model was built on the 
remaining seventeen cases and forty-two controls with a low or intermediate 
risk assessment, all type I tumors.  A discrimination between the two groups 
could now be seen in the sPLS-DA score plots (fig. 15, b).  
 
This sPLS-DA model explained 38.1% of the variance with the first two 








Figure 15 a and b: sPLS-DA score plot of the serum metabolome from the cases with chronic 
postoperative pain (red dots) and controls without chronic postoperative pain (green dots).  
(a) the sPLS model with twenty-six cases and fifty-two controls. (b) the sPLS-DA model 
constructed for seventeen cases and forty-two controls after data set was synchronized. 
Reprint from Chronic Postoperative Pain After Hysterectomy for Endometrial Cancer: A Metabolic 
Profiling Study. Lunde et al. Molecular Pain. Volume 16, May 2020, 1-7. 
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4.2.3. IDENTIFICATION OF DETECTED METABOLITES 
A total of one-hundred and forty-seven metabolites were identified and 
classified into sub-groups of  cholesterol; glycerides and phospholipids; 
apolipoproteins; fatty acids; amino acids; glycolysis related metabolites; 
ketone bodies; fluid balance; inflammation and lipoproteins2. Please refer to 
the supplemental table in appendices for an overview (Paper II). 
 
Twenty metabolites which belong to fatty acids, amino acids, glycolysis related 
metabolites and lipoprotein groups were identified as the most influential 
factors for the difference between case and control groups. Of these, nineteen 
metabolites, including cholesterol, linoleic acid (LA), phospholipids, lipids and 
triglycerides, demonstrated statistically significant higher concentrations in the 
case group than in the control group (p < 0.05), while the concentration of 
glycerol was statistically significant lower in the case group than in the control 
group (p < 0.05) (fig. 16)2. 
 
Fourteen of these metabolites were found to be the leading contributing 
metabolites correlated to chronic postoperative pain, based on a combination 
of high loadings scores and valid AUC values (equal or higher than 0.7). Their 














Figure 16: Loading plots from the cases with chronic postoperative pain and controls without 
chronic postoperative pain. High concentrations are depicted as red boxes, while low 
concentrations are depicted as green boxes. 
Low density lipoproteins (LDL); Intermediate density lipoproteins (IDL); Very low density 
lipoproteins (VLDL); Free cholesterol in very small VLDL (XS-VLDL-FC); Triglycerides in IDL 
(IDL-TG); Triglycerides in large LDL (L-LDL-TG); Triglycerides in LDL (LDL-TG); Triglycerides in 
medium LDL (M-LDL-TG); Concentration of very small VLDL particles (XS-VLDL-P); Total lipids 
in very small VLDL (XS-VLDL-L); Triglycerides in small LDL (S-LDL-TG); Phospholipids in very 
small VLDL (XS-VLDL-PL); Triglycerides in very small VLDL (XS-VLDL-TG); Cholesterol in very 
small VLDL (XS-VLDL-C); Linoleic acid (LA); Isoleucine (Ile); Cholesterol in small VLDL (S-VLDL-
C); Concentration of IDL particles (IDL-P); Total lipids in IDL (IDL-L); Cholesteryl esters in small 
VLDL (S-VLDL-CE); Remnant cholesterol i.e. non-HDL, non-LDL-cholesterol (Remnant-C) and 
Cholesteryl esters in very small VLDL (XS-VLDL-CE). 
Reprint from Chronic Postoperative Pain After Hysterectomy for Endometrial Cancer: A Metabolic 
Profiling Study. Lunde et al. Molecular Pain. Volume 16, May 2020, 1-7. 
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Metabolite Area under the curve (AUC) p-value Log2 Fold Change 
IDL-TG 0.80 0.01 0.37 
LDL-TG 0.80 0.01 0.35 
L-LDL-TG 0.80 0.01 0.35 
M-LDL-TG 0.79 0.01 0.34 
S-LDL-TG 0.79 0.01 0.36 
XS-VLDL-FC 0.78 0.01 0.30 
XS-VLDL-TG 0.76 0.01 0.40 
XS-VLDL-L 0.75 0.01 0.30 
XS-VLDL-P 0.75 0.01 0.26 
Glycerol 0.74 0.01 -0.48 
XS-VLDL-PL 0.73 0.01 0.28 
XS-VLDL-C 0.73 0.01 0.28 
LA 0.71 0.01 0.18 
Ile 0.70 0.02 0.30 
 
4.2.4. PREDICTION MODELS FOR CHRONIC POSTOPERATIVE PAIN 
The fourteen metabolites were used to build prediction models for chronic 
postoperative pain through four machine learning algorithms, all of which 
exhibited high AUC values (0.79-0.87) and coefficients of variation prediction 
(0.70-0.77) (table 10)2. 
 
Algorithm Area under the curve  
(AUC) 
Coefficient of variation 
prediction 
p-value 
PLS-DA 0.79 (0.53-0.93) 0.70 0.01 
Linear support vector 0.87 (0.69-0.97) 0.77 < 0.001 
Logistic regression 0.80 (0.54-0.97) 0.74 0.005 
Random forest 0.82 (0.70-0.93) 0.71 < 0.001 
Table 9: Area under the curve (AUC), p-value and log 2-fold change for a set of 14 metabolites.  
Low density lipoproteins (LDL); Intermediate density lipoproteins (IDL); Very low density 
lipoproteins (VLDL); Triglycerides in IDL (IDL-TG); Triglycerides in LDL (LDL-TG); Triglycerides 
in large LDL (L-LDL-TG); Triglycerides in medium LDL (M-LDL-TG); Triglycerides in small LDL 
(S-LDL-TG); Free cholesterol in very small VLDL (XS-VLDL-FC); Triglycerides in very small VLDL 
(XS-VLDL-TG); Total lipids in very small VLDL (XS-VLDL-L); Concentration of very small VLDL 
particles (XS-VLDL-P); Phospholipids in very small VLDL (XS-VLDL-PL); Cholesterol in very 
small VLDL (XS-VLDL-C); Linoleic acid (LA) and Isoleucine (Ile). 
Reprint from Chronic Postoperative Pain After Hysterectomy for Endometrial Cancer: A Metabolic 
Profiling Study. Lunde et al. Molecular Pain. Volume 16, May 2020, 1-7. 
Table 10: Prediction models based on a set of 14 metabolites distinguishing case from control 
groups. Data in parenthesis represents the 95% confidence intervals. 
Reprint from Chronic Postoperative Pain After Hysterectomy for Endometrial Cancer: A 
Metabolic Profiling Study. Lunde et al. Molecular Pain. Volume 16, May 2020, 1-7. 
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4.3. STUDY III 
One-hundred-and-seventy-three patients were diagnosed with endometrial 
cancer and scheduled for surgery from August 1st, 2015 till December 31st, 
2018. Thirteen patients either declined to participate or were excluded. The 
remaining one-hundred-and-sixty patients were included prior to surgery (fig. 
17). 
 
Figure 17: Flowchart of Study III. 
Reprint from Preoperative Quantitative Sensory Testing and Robot-Assisted Laparoscopic 
Hysterectomy for Endometrial Cancer: Can Chronic Postoperative Pain be Predicted?  
Lunde et al. Scandinavian Journal of Pain, E-pub. ahead of print, August 2020, 1-13. 
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Three included patients were inoperable due to comorbidity or stage of cancer 
and three other patients died during the six months follow-up. A total of one-
hundred-and-fifty-four questionnaires were mailed out and one-hundred-and-
forty (90.9%) were returned, while fourteen (9.1%) questionnaires were not 
returned within 5 weeks3. 
 
4.3.1. NON-RESPONDER ANALYSIS 
No statistically significant difference was found between responders (n = 140) 
and non-responders (n = 14) in terms of age, BMI, duration of surgery or blood 
loss3. 
 
4.3.2. TUMOR CHARACTERISTICS 
As supplemental material to Paper III, the tumor characteristics of the 
responders are shown in table 11. 
 
   
Tumor characteristics (n = 140)              n (%)  
Histologic type and grade  
    Endometrioid carcinomas 
 
          Endometrioid adenocarcinomas  121 (86.4) 
                Grade 1 
                Grade 2 
                Grade 3 
    Non-endometrioid carcinomas   
          Serous adenocarcinomas                                   
          Clear cell adenocarcinomas  
          Carcinosarcomas                
    Sarcomas 
          Adenosarcomas 
 
FIGOa stage 
    IA 
    IB 
    II 
    III 
    IV 
89 (63.6)   
















Table 11: Tumor characteristics. Data displayed as n (%). aFédération Internationale de 





4.3.3. CHRONIC POSTOPERATIVE PAIN 
The prevalence of chronic postoperative pain was 13.6% (95% CI 8.4-20.4) 
equivalent to 19 patients which were grouped as ‘Chronic pain’, while the 
remaining 121 patients were grouped as ‘No chronic pain’. An independent 
samples t-test demonstrated that the patients with chronic pain had a lower 
BMI (p = 0.032), a higher prevalence of preoperative pelvic pain (p < 0.001), 
and a higher level of acute postoperative pain (p < 0.001) when compared to 
patients without chronic pain (table 12). No difference in the distribution of 
histopathologic diagnose and stage of cancer was found between the ‘Chronic 
pain’ and ‘No chronic pain’ groups (data not shown)3.  
 
Study parameter Chronic pain 
(n = 19) 
No chronic pain 
(n = 121) 
p-value 
Age (years) 64.2 ± 10.0 66.4 ± 8.9 0.321 
BMIa (kg/m2) 26.2 ± 7.3 29.9 ± 6.7 0.032* 
Preoperative pelvic pain (%) 11/19 (57.9%) 21/121 (17.4%) 0.001* 
Blood loss during surgery (mL) 64.7 ± 47.6 76.9 ± 79.7 0.521 
Duration of surgery (min) 60.3 ± 22.1 64.7 ± 25.5 0.480 
Level of acute postoperative pain (VASb) 5.8 ± 2.0 3.1 ± 2.7 0.001*  
 
4.3.4. QUANTITATIVE SENSORY TESTING  
No statistically significant difference was found between the ‘Chronic pain’ and 
the ‘No chronic pain’ group when applying handheld algometry (fig. 18, A), 
cuff pressure algometry (fig. 18, B), temporal summation of pain (fig. 18, C) or 
conditioned pain modulation (fig. 18, C). During thermal stimulation, the 
‘Chronic pain’ group demonstrated statistically significant lower HPT 
compared with the ‘No chronic pain’ group (40.9°C versus 42.6°C, p = 0.043) 
while no statistically significant difference between groups was found in WDT 
(fig. 18, D)3. 
Table 12: The sub-grouped patients with and without chronic postoperative pain. Results are 
displayed as mean ± SD for continuous variables and as proportions with corresponding 
frequencies for categorical variables. aBody Mass Index (BMI), bVisual Analogue Scale (VAS). 
*Statistically significant difference between groups (p < 0.05). 
Reprint from Preoperative Quantitative Sensory Testing and Robot-Assisted Laparoscopic 
Hysterectomy for Endometrial Cancer: Can Chronic Postoperative Pain be Predicted?  
















Figure 18 A and B: Preoperative Quantitative Sensory Testing of patients with (gray) and without 
(green) chronic postoperative pain. Results are displayed as mean ± SD.  
(A) Handheld Algometry. Pressure Pain Thresholds (PPT) at three locations.  
(B) Cuff Pressure Algometry. Pain Detection Thresholds (PDT) and Pain Tolerance Thresholds 
(PTT).  
Reprint from Preoperative Quantitative Sensory Testing and Robot-Assisted Laparoscopic 
Hysterectomy for Endometrial Cancer: Can Chronic Postoperative Pain be Predicted?  








Figure 18 C and D: Preoperative Quantitative Sensory Testing of patients with (gray) and without 
(green) chronic postoperative pain. Results are displayed as mean ± SD, except results from the 
thermal stimulation which are displayed as mean and range. 
(C) Conditioned Pain Modulation (CPM) and Temporal Summation of Pain (TSP).  
(D) Thermal Stimulation. Warm Detection Thresholds (WDT) and Heat Pain Thresholds (HPT). 
*Statistically significant difference between groups (p < 0.05). 
Reprint from Preoperative Quantitative Sensory Testing and Robot-Assisted Laparoscopic 
Hysterectomy for Endometrial Cancer: Can Chronic Postoperative Pain be Predicted?  




4.3.5. THE BINARY LOGISTIC REGRESSION MODEL 
A binary logistic regression model was built using only the preoperative study 
parameters HPT, BMI and presence of preoperative pelvic pain. The model 
had a Nagelkerke R2 value of 0.251, indicating the model’s goodness-of-fit 
between 0-1, i.e. 25.1% of the difference in one variable can be explained by 
the difference in a second variable, when predicting chronic postoperative 
pain3. The model showed preoperative pelvic pain as significant, independent 
predictive risk factor of chronic postoperative pain (OR = 6.62, 95% CI 2.26-
19.44) (table 13)3. 
 
Study parameter OR 95% CI 
Heat Pain Threshold 0.86 0.72 – 1.02 
BMIa 0.92 0.85 – 1.00 
Preoperative pelvic pain 6.62 2.26 – 19.44  
As shown in table 13, the model furthermore indicated a trend towards Heat 
Pain Thresholds and BMI as independent risk factors, i.e. a high Heat Pain 
Threshold and a high BMI reduced the risk of chronic postoperative pain3. 
 
  
Table 13: The binary logistic regression model with three predictive factors for development of 
chronic postoperative pain. Results are displayed as Odds Ratio (OR) and the 95% Confidence 
Interval. aBody Mass Index (BMI). 
Reprint from Preoperative Quantitative Sensory Testing and Robot-Assisted Laparoscopic 
Hysterectomy for Endometrial Cancer: Can Chronic Postoperative Pain be Predicted?  







CHAPTER 5. DISCUSSION 
This chapter will focus on an overall discussion of the main results in relation 
to our aims and hypotheses, and the existing literature. 
 
5.1. THE PREVALENCE OF CHRONIC POSTOPERATIVE PAIN 
The prevalence of chronic postoperative pain after robot-assisted 
hysterectomy for endometrial cancer was found to be 14.9% (95% CI 10.4-
20.6) in Study I, which was supported by an equivalent finding in Study III with 
a prevalence of 13.6% (95% CI 8.4-20.4). 
 
The subsequent, imperative question is: Does the questionnaire in fact 
measure the prevalence of chronic postoperative pain in our study groups? 
While this question is simple to ask, an unambiguous answer is harder to give. 
As shown in section 1.4., studies have found a prevalence of chronic pelvic 
pain of 7.4% in the background population of the age group in question144. 
This can in part be explained by an accumulated number of comorbidities as 
discussed in section 1.3.1127–129. Whether this prevalence of chronic pain in 
the background population can be applied to our study group is also difficult 
to answer. From Study I, table 4 we see that 16.9% of the responders 
indicated a preoperative pain condition1. From a methodological point of view, 
one could argue that only the difference in the prevalence between 
preoperative- and postoperative pain reflects the effect of the surgical 
procedure. Nevertheless, this approach would be too crude, as table 5 shows 
that only 51.6% (95% CI 33.1-69.8) of the responders with postoperative pain 
also had preoperative pain. In other words, nearly half of the responders with 
postoperative pain developed this condition after the surgical procedure had 
taken place. Still, the expected level of pain in the background population is 
important to take into consideration when consulting patients prior to surgery. 
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In a recent, prospective cohort study of patients who underwent abdominal or 
laparoscopic hysterectomy for benign conditions, Sng et al found a prevalence 
of chronic postoperative pain (VAS ≥3) of 15.7%, 6 months after surgery201. 
Similar findings were made by Brandsborg et al 4 months after vaginal, 
abdominal or laparoscopic hysterectomy on benign indication, with a 
prevalence of chronic postoperative pain (VAS ≥3) of 17.0%202. 
 
Following abdominal hysterectomy, Stovall et al found a prevalence of chronic 
postoperative pain of 22.2% and Hillis et al found a prevalence of 26.0%64,65. 
Both studies, however, had chronic pelvic pain of presumed uterine etiology 
as indication for hysterectomy which is of paramount importance when 
comparing these studies. As shown in Study I and III, the presence of 
preoperative pelvic pain is associated with the risk of developing chronic 
postoperative pain by a factor 4.99 (95% CI 4.15-5.83) (Study I) to 6.62 (95% 
CI 2.26-19.44) (Study III). Therefore, we would a priori expect a higher 
prevalence in these populations, seeing that all of the study participants had 
preoperative pelvic pain. In another study, Brandsborg et al examined the 
prevalence of chronic postoperative pain following abdominal, vaginal or 
laparoscopic hysterectomy due to a broader range of benign indications like 
leiomyomas, dysmenorrhea or endometriosis61. The prevalence of chronic 
postoperative pain in this study was found to be 31.9%. These benign 
indications are, nevertheless, also associated with an increased prevalence 
of preoperative pelvic pain, consequently increasing the expected number of 
patients suffering from chronic postoperative pain109. In contrast, the sole 
indication for hysterectomy in Study I-III was endometrial cancer, which rarely 
causes pain in early stage disease. 
 
The divergence in the indication for hysterectomy was further reflected in the 
mean age of the study participants, where they in Brandsborg’s study had a 
mean age of 48 years, compared to a mean age of 67 years in Study I. This 
difference in mean age alone could explain some of the discrepancy, seeing 
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that research has shown high age to be a protective factor of chronic 
postoperative pain93,203. This trend was also indicated in Study I by the logistic 
regression model, where age had an OR of 0.94 (95% CI 0.88-1.00) (table 7). 
Accordingly, one would assume that the prevalence of chronic postoperative 
pain was higher in a younger population. The abundant definitions of chronic 
postoperative pain applied in various studies may also explain some of the 
variance of the reported findings. In a multicenter cohort study by Theunissen 
et al they examined three-hundred and seventy-six patients scheduled for 
abdominal, vaginal or laparoscopic hysterectomy on benign indication. They 
demonstrated a prevalence of chronic postoperative pain of 9.0% 12 months 
after the surgical procedure, when defining chronic postoperative pain as 
persistent pain with a VAS ≥ 4136. Other studies of pain following 
hysterectomy, like our Study I-III, defined chronic postoperative pain as 
persistent pain with a VAS ≥ 3 after 6 months, while Brandsborg et al in a later 
study from 2009 defined any persistent pain (VAS >0) after 4 months as 
chronic postoperative pain and found a prevalence of 16.7%185. Using a 
parallel definition of chronic postoperative pain (NRS >0), but 6 months after 
vaginal or laparoscopic hysterectomy on benign indication, Pokkinen et al 
found a prevalence of 26.0%62.  
 
As the examples above amply demonstrate, a consensus-based definition of 
chronic postoperative pain is critically needed. This will in part be achieved in 
the upcoming, revised version of the WHO’s International Classification of 
Diseases (ICD-11), where the IASP have agreed upon a definition of chronic 
postoperative pain as persistent pain at least 3 months after the surgical 
procedure, while no definition of the pain intensity is included204. Considering 
that the indication for hysterectomy is of utmost importance when assessing 
the risk of chronic postoperative pain and the fact that dissimilar definitions of 
chronic postoperative pain are being applied, it is necessary to exhibit some 




5.2. THE CHARACTERISTICS OF POSTOPERATIVE PAIN 
Amongst the thirty-one patients with chronic postoperative pain in Study I, the 
pain was most prominent during heavy lifts (48.4%), sexual intercourse 
(29.0%) and while running (25.8%)1. The pain had a daily mean intensity of 
3.6 NRS and 5.7 NRS when at worst, which supports the findings of the 2007 
study by Brandsborg et al (with a daily mean intensity of 4.0 NRS and 6.0 NRS 
when at worst)61. 
 
In a study from 2016, Pokkinen et al characterized persistent pain after 
hysterectomy by gynecological and sensory examination101. Here the authors 
found that persistent pain in most cases exhibited the characteristics of 
neuropathic pain and could be categorized as chronic postoperative pain101.  
In Study I, the pain was located at the areas corresponding to dermatomes T-
12–L-3 and S-2–S-4 (fig. 13)1. These are the same spinal segments that 
receive afferent sensory neurons from the uterus and adnexa, thus supporting 
the theory of referred visceral pain205. This aligns with the findings of 
experimental pain models, where cervical distension triggered similar visceral 
pain206,207. 
 
In our studies, these characteristics and intensities of chronic postoperative 
pain is the closest approximation to the impact on everyday activities. 
However, as discussed in section 1.1.5, chronic postoperative pain is merely 
one aspect in the overall Health-Related Quality of Life (HRQoL) for these 
patients. Therefore, it would have been desirable to have obtained data on the 
HRQoL using for instance the EORTC QLQ-C30 and QLQ-EN24 
questionnaires45–47. This would have allowed for a more nuanced and 






5.3. SELECTED RISK FACTORS 
Aim II and VI of this dissertation were to assess selected risk factors for 
development of chronic postoperative pain. From Study I we could conclude 
that the presence of preoperative pelvic pain was a significant, independent 
risk factor with an adjusted OR of 4.99 (95% CI 4.15-5.83) (table 7, model 2). 
This was further substantiated by Study III, where the presence of 
preoperative pelvic pain had an OR of 6.62 (95% CI 2.26-19.44) (table 13). 
This is fully in agreement with the existing literature, as preoperative pain is a 
well-known risk factor for chronic postoperative pain after hysterectomy and 
other types of surgery, e.g. inguinal hernia repair, caesarean section, 
mastectomy and postamputation phantom pain61,93,185,201,203,208–212. As shown 
in section 4.1.5., the unadjusted odds ratio for preoperative pelvic pain as a 
risk factor for development of chronic postoperative pain was 8.81 (95% CI 
3.43-22.38) while the adjusted odds ratio as mentioned above was 4.99 (95% 
CI 4.15-5.83). This discrepancy indicates that the unadjusted odds ratio was 
confounded. Confounding will be addressed in section ‘5.6. Methodological 
Considerations’. 
 
Study I further showed a high level of acute postoperative pain to be a 
significant, independent risk factor with an OR of 1.27 (95% CI 1.09-1.45) 
(table 7, model 2), which also concurs with previous findings203,213. This risk 
factor was not tested in Study III as we only assessed selected preoperative 
risk factors in this study. In Hypothesis Ig we conjectured that the development 
of chronic postoperative pain was associated with the presence of 
preoperative pelvic pain and acute postoperative pelvic pain, which was found 
 
g Hypothesis I: Development of chronic postoperative pain is associated to the pre- and 
postoperative risk factors: presence of preoperative pelvic pain, acute postoperative 
pelvic pain, age, severity of cancer, operating time, blood loss, educational level and 
employment status. (Section 2.1.). 
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to be true. In Study III we tested Hypothesis IVh, where the presence of 
preoperative pelvic pain was associated to chronic postoperative pain. Neither 
age, severity of cancer, operating time, blood loss, educational level nor 
employment status, however, was associated with the development of chronic 
postoperative pain. 
 
5.4. METABOLIC PROFILING 
Aim III of this dissertation was to investigate the serologic composition of 
lipids, lipoproteins and other low-molecular metabolites in preoperative blood 
samples from patients with chronic postoperative pain, hypothesizing that 
these patients had a distinctive metabolic profile compared to patients without 
chronic postoperative pain (Hypothesis IIi). Study II showed that metabolic 
profiling by NMR could not discriminate between these two groups when 
including patients of all ESMO-ESGO-ESTRO risk assessments2. In a large 
subgroup of patients with low and intermediate risk assessment (75.6% of all 
patients), nevertheless, a discrimination model could be built2. This necessity 
to differentiate the risk groups could underline the inherent biological 
heterogenicity between type I and type II tumors, seeing that all type II tumors 
were excluded in this secondary analysis. Despite the results of this 
secondary analysis, we must reject our initial Hypothesis II, as it included all 
ESMO-ESGO-ESTRO risk assessments groups. 
 
 
h Hypothesis IV: Development of chronic postoperative pain is associated to the 
preoperative risk factors: presence of preoperative pelvic pain, age, severity of cancer, 
educational level and employment status. (Section 2.3.). 
i Hypothesis II: Patients who develop chronic postoperative pain have a distinctive 
preoperative serologic composition of lipids, lipoproteins and other low-molecular 




The concentration of nineteen metabolites were found to be significantly 
higher in the group of patients, that developed chronic postoperative pain, 
compared to the control group that did not develop chronic postoperative 
pain2. These metabolites included cholesterol, linoleic acid (LA), 
phospholipids, lipids and triglycerides. These findings are well in accordance 
with recent literature, as mentioned in section ‘1.2.7 Pro- and Antinociceptive 
Modulators’, where LA and other omega-6 derivatives have been shown to 
form a pronociceptive cellular environment thus promoting the induction and 
perpetuation of chronic pain83. 
 
Additionally, studies have shown that cholesterol can act as a modulator of 
opioid receptors in the cellular membrane, thereby modifying the perception 
of pain and the intrinsic susceptibility to endogenous and exogenous 
opioids214–216. This association was also shown in both animal and human 
studies, where individuals with a high serum cholesterol level required a 
smaller dose of opioid to achieve an equivalent analgesic effect, compared to 
individuals with a low serum cholesterol level217,218. 
 
Aim IV was to determine if an array of serological biomarkers were predictive 
for development of chronic postoperative pain. The sPLS-DA model of Study 
II had a predictive accuracy of 73.1%2. Again, despite the noteworthy results 
of this explorative study we must reject Hypothesis IIIj as it did not include all 
ESMO-ESGO-ESTRO risk assessments groups. Nonetheless, future 
metabolic studies are warranted as this novel field of research holds a 
promising capacity to uncover some of the intricate pathophysiologic pain 
mechanisms on a molecular level. 
 
 
j Hypothesis III: Serologic biomarkers of lipids, lipoproteins and other low-molecular 




5.5. QUANTITATIVE SENSORY TESTING 
As described in the results section of Study III, significant heat pain 
hyperalgesia (40.9°C versus 42.6°C) was found in the group of patients that 
would develop chronic postoperative pain at a later stage compared to 
patients that would not develop chronic postoperative pain3. The association 
between HPT and chronic postoperative pain, however, was non-significant 
in a binary logistic regression model (OR = 0.86 (95% 0.72-1.02) (table 13)). 
None of the other QST modalities showed any statistically significant 
difference between groups. Therefore, we must conclude that none of the 
tested QST modalities could predict development of chronic postoperative 
pain - and consequently reject Hypothesis Vk. 
 
As demonstrated in fig. 18, the ‘Chronic pain’ group consistently exhibited 
lower mean values of PPT, PDT, PTT and TSP than the ‘No chronic pain’ 
group. These findings, however, were non-significant due to the broad 
distributions of data. This could indicate that the study was underpowered, 
seeing that a larger sample size theoretically would render narrower 
confidence intervals, thus hypothetically making the differences of the means 
statistically significant. It is important to note, that this was not the case for the 
CPM and WDT values, where the ‘Chronic pain’ group did in fact exhibit higher 
mean values than the ‘No chronic pain’ group. 
 
Pan et al found heat pain thresholds to be predictive of postoperative pain in 
a study of thirty-four patients scheduled for cesarean section219. Supra-
threshold heat pain was found to be predictive by Granot et al and Werner et 
 
k Hypothesis V: Quantitative sensory testing by handheld algometry, cuff pressure 
algometry, temporal summation of pain, conditioned pain modulation and heat evoked 
pain can predict development of chronic postoperative pain. (Section 2.3.). 
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al when examining postoperative pain following respectively cesarean section 
and arthroscopic knee surgery220,221. 
 
Postoperative pain following hysterectomy on benign indication has only been 
the subject of fairly few QST studies, one of them being the study by 
Brandsborg et al from 2011. Here they examined ninety patients with a mean 
age of 46 years with QST methods for brush-evoked allodynia, pinprick 
hyperalgesia, wind-up-like pain as well as abdominal and vaginal pressure 
pain thresholds202. The results showed a relatively high frequency of 
preoperative pelvic pain of 51%, despite the fact that known endometriosis 
and / or pelvic pain as main indication for hysterectomy were exclusion criteria. 
In this sub-group of patients with preoperative pelvic pain they found 
significant brush-evoked allodynia, pinprick hyperalgesia and decreased 
abdominal and vaginal pressure pain thresholds202. Preoperative brush-
evoked allodynia, pinprick hyperalgesia, and vaginal pressure pain threshold 
were all associated with the intensity of acute postoperative pain, while 
only preoperative brush allodynia was weakly associated to chronic pain after 
4 months202. The results of Brandsborg’s study indicate that patients with 
preoperative pelvic pain exhibited some degree of central sensibilization with 
cutaneous hyperalgesia and allodynia as well as the phenomenon of viscero-
somatic convergence (as described in section ‘1.2.4. Visceral Pain’)167,222.  
 
Other QST studies in the field of gynecology have mainly focused on chronic 
pelvic pain in endometriosis. In a study by Grundström et al they performed 
QST tests of thirty-seven patients with persistent pelvic pain suspected of 
endometriosis and found lower thresholds for heat, cold and pressure pain 
when compared to fifty-five healthy controls, thereby further substantiating the 





During the last decades, several studies have shown the predictive 
capabilities of various QST modalities, while other studies have failed to do 
so. This inconsistency was further demonstrated in a systematic review of 30 
studies on 2,738 subjects by Sangesland et al in 2017224. Here the authors 
concluded:  
“The majority of the preoperative QST variables showed no 
consistent association with pain intensity after surgery. Thermal 
heat pain above the pain threshold and temporal summation of 
pressure pain were the QST variables, which showed the most 
consistent association with acute or chronic pain after surgery.” 224 
   
In another systematic review on the topic published by Petersen et al in July 
of 2020, the authors also found inconsistent results and heterogeneous 
methodologies across 25 studies of QST and chronic postoperative pain225.  
As shown by both systematic reviews, one of the major challenges facing QST 
as a research field is the lack of standardized test paradigms resulting in a 
considerable variance of the outcome data.  
 
Recently, measures are being taken towards a standardization through 
guidelines for test algorithms as well as development of novel QST methods 
to decrease the intra- and interobserver variability181,196,226. Finally, for QST to 
be adopted in a clinical setting, there is a need for unambiguous, large-scale 
studies demonstrating an ability to distinctly differentiate patients at risk of 
developing chronic postoperative pain or to facilitate improvements in the 







5.6. METHODOLOGICAL CONSIDERATIONS 
Any research methodology holds strengths and limitations which are essential 
to reflect upon. These methodological considerations are presented in the 
following section. 
 
5.6.1. STUDY I 
The Measure of Association 
The probability of a certain event can be represented in different epidemiologic 
terms. In medical studies, the relative risk (RR) and the Odds Ratio (OR) are 










when utilising the terminology from table 14, showing the generic outcome 
groups in a hypothetical study. 
 
 
Diseased Healthy         Total 
Exposed DE HE                            NE 
Not exposed DN HN                            NN 
 
Table 14: Tabulated generic outcome groups. 
Adapted and revised from Morris and Gardner. Statistics in Medicine: Calculating confidence 
intervals for relative risks (odds ratios) and standardised ratios and rates. Br Med J (Clin Res Ed). 
1988 May 7; 296(6632): 1313–1316. 
 
From the definitions of RR and OR it is apparent that the OR is an 
approximation of the corresponding RR in cases of rare diseases, while the 
OR will be further from 1.0 than the RR in cases of common diseases 
(approximately >10%)228. This is known as ‘The rare disease assumption’ and 
is important to take into account229.  
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An example of this phenomenon is shown in table 15, where the outcome of 
5 different interventions are shown with the corresponding OR and RR 
calculations. 
 
 Deaths Survivors Odds of death OR Risk of death RR 
Intervention 1 10 90 10/90 = 0.11 0.11/0.11  10/100 = 0.10 0.10/0.10  
Control 10 90 10/90 = 0.11 = 1.0 10/100 = 0.10 = 1.0 
       
Intervention 2 1 99 1/99 = 0.01 0.01/0.11  1/100 = 0.01 0.01/0.1  
Control 10 90 10/90 = 0.11 = 0.09 10/100 = 0.10 = 0.10 
       
Intervention 3 3 97 3/97 = 0.0309 0.0309/0.0101  3/100 = 0.03 0.03/0.01  
Control 1 99 1/99 = 0.0101 = 3.06 1/100 = 0.01 = 3.0 
       
Intervention 4 30 70 30/70 = 0.43 0.43/0.11  30/100 = 0.30 0.30/0.10  
Control 10 90 10/90 = 0.11 = 3.9 10/100 = 0.10 = 3.0 
       
Intervention 5 45 55 45/55 = 0.82 0.82/0.11  45/100 = 0.45 0.45/0.1  
Control 10 90 10/90 = 0.11 = 7.45 10/100 = 0.1 = 4.5 
Table 15: Hypothetical example to illustrate the difference between Odds ratio (OR) and Relative 
Risk (RR) in 5 cases. 
Reprint from Ranganathan et al. Common pitfalls in statistical analysis: Odds versus risk. 
Perspect Clin Res 2015;6:222-4 
 
Clearly, the OR approximates the RR in intervention 1-3, while the OR is 
significantly higher than the RR in intervention 4-5230. In Study I and III, this 
phenomenon is also present as the outcome (chronic postoperative pain) has 
a prevalence of 13.6-14.9% and thus can be considered as relatively common 
in respect to ‘The rare disease assumption’.  
 





    Postoperative pain Total 
      + -   
Preoperative pain  + 16 19 35 
  - 15 157 172 
Total   31 176 207 
 












15	/	157 = 8.81 
 
As this part of Study I was designed as a cohort study, the preferred measure 
of association would be the RR200. However, as we use binary logistic 
regression models to estimate the risk factors for a dichotomous outcome 
(chronic postoperative pain: yes or no) the measure of association is OR by 
default. Nevertheless, the distinction between RR and OR is imperative when 
using the results of studies like our own to counsel patients prior to surgery. 
 
Information Bias 
If a measurement instrument does not measure what it was intended to 
measure, it can generate systematic misclassification, and as such, be 
classified as information bias231,232. As stated in section 5.1., the fundamental   
question in our studies is: Does the questionnaire in fact measure chronic 
postoperative pain? To answer this, we must consider the validation of the 
questionnaire. As described in section 3.3., the questionnaire was validated 
through pilot testing with verbal probing and face- and content validation. 
Despite this validation process is similar to other studies of chronic pain 
following hysterectomy, this must be considered scarce from a methodological 
point of view62,186,233,234. The principal shortcomings are the undetermined 
construct validity and reliability of the questionnaire.  
 
 
Table 5: Cross tabulation of the variables pre- and postoperative pain among patients.  




In our case, the construct validity would describe to which extent the 
questionnaire did indeed measure chronic postoperative pain. This can be 
assessed by evaluating the association to other variables, to which the 
construct should be positively or negatively correlated190,235. Often, this is done 
by comparing the scores from the newly developed questionnaire to the 
scores of a previously validated questionnaire (from the same individual, at 
the same point in time)235. If the questionnaires were designed to measure the 
same constructs, we would expect a positive correlation - and if the 
questionnaires were not designed for the same construct, we would expect no 
correlation (or a negative correlation, if the constructs we inversely 
related)235,236. In our case, scores from the questionnaire could have been 
compared to scores from the Brief Pain Inventory questionnaire, where we 
would expect some degree of overlapping constructs183,184. Another method 
for assessing the construct validity would be a confirmatory factor analysis186. 
Here, factors in the questionnaire - which we a priori know to be related - are 
tested via a combination of a multivariate analysis and a principal component 
analysis (as described in section 3.8.2)186,237.  
 
The reliability of the questionnaire would describe to which extent the 
questionnaire measured chronic postoperative pain with consistency and 
reproducibility234. Generally, the reliability is divided into the internal 
consistency, the test-retest reliability, and the inter-rater reliability234,237. The 
internal consistency describes to which extent the items are consistent in 
measuring the same construct190. Traditionally, this is described in terms of a 
coefficient ranging from 0 to 1, entitled Cronbach's alpha234,236. A Cronbach's 
alpha value below 0.7 generally indicate low consistency, while a high value 
above 0.9 could indicate redundancy238,239. Another method to test the internal 
consistency is known as split-half reliability, in which the consistency of half of 
the items are correlated to the consistency of the other half, expressed by a 
Spearman-Brown coefficient239–241.  
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The test-retest reliability describes to which extent the answers given by a 
responder remain consistent when the questionnaire is filled out twice or 
more234,237. This is typically described using Pearson's correlation coefficient 
ranging from -1 to 1, where high positive values indicate a strong test-retest 
reliability237. Finally, the inter-rater reliability describes to which extent 
answers to the same question correlates when given to different data 
gatherers, and can be expressed using several different correlation 
coefficients237,239. 
 
The scarce validation process of our questionnaire is a severe inadequacy, 
which comprises the generalizability of our results. A systematic and 
methodical validation of the questionnaire prior to initiating these studies 
would have been appropriate. Despite this understanding came post festum, 
it would, nevertheless, be essential to perform a thorough validation of the 
questionnaire, if it was to be utilized in future studies. 
 
As stated in section ‘1.5. Assessment of Pain’, the subjective nature of pain 
entails an inherent challenge when trying to assess and quantify pain as an 
outcome measure. Firstly, the use of questionnaires and other types of self-
reported data can - and probably always will - introduce an element of 
information bias, as responders are asked for a (subjective) assessment of a 
given variable. The responders might remember details inaccurately (recall 
bias), unconsciously exaggerate or underestimate - or simply choose to give 
an answer which is not truthful. Secondly, the need for an operational 
definition of chronic postoperative pain (in this PhD dissertation, persistent, 
moderate to severe pain on a daily basis with a mean VAS ≥ 3, six months 
after the surgical procedure) reduces the complex condition of postoperative 
pain to a simple, binary outcome. This necessary - yet somewhat 
oversimplified - definition will irrefutably lead to a risk of misclassification, as 
some individuals might indeed have a mean VAS ≥ 3 while not being impaired 
by this level of chronic pain. 
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As shown by the literature review in section ‘1.5.2. The Memory of Pain’, 
several studies have shown that pain is recalled accurately after six months. 
In the studies presented in this PhD dissertation, the risk of recall bias is 
mainly a concern in Study I given its retrospective nature. From table 2 it is 
seen that the mean follow-up time (i.e. the number of days between the 
surgical procedure and receiving the questionnaire) was 1,053.2 days 
equivalent to 2.9 years. Keeping this in mind, it is apparent that the answers 
related to the preoperative time period could have inherent issues of recall 
bias in spite of the general accuracy of recalled pain. If all study participants 
(with or without chronic pain) recalled the level of pain equally poor this would 
lead to non-differential misclassification, which theoretically would weaken the 
measure of association (and bias toward the null)200. More problematic is the 
case of differential misclassification, where for instance study participants with 
chronic postoperative pain falsely recall a higher level of preoperative pain. 
This would lead to systematic bias and potentially demonstrate an incorrect 
measure of association between preoperative pain and postoperative 
pain200,231. The risk of differential or non-differential misclassification due to 
recall bias cannot be disregarded in this study. 
 
Selection Bias 
Study I had a responder rate of 76.1% and thereby above the conventional, 
recommended minimal responder rate of 75.0%, thus minimizing the 
likelihood of non-response bias242,243.  
 
The non-responder analysis did not show any statistically significant 
difference in BMI, duration of surgery or blood loss between responders and 
non-responders. The mean age, nevertheless, was significantly lower in the 
non-responder group compared to the responders (63.4 years, 95% CI 60.6-
65.7 versus 67.2 years, 95% CI 65.9-68.5), thereby indicating selection bias 
seeing that the individuals were not equally balanced between the two groups. 
A hypothetical explanation for this discrepancy could be that the willingness 
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to participate in a questionnaire study depended on age or whether the 
individual had retired. As the age of retirement in Denmark was 65 years-of-
age at the time of the study, this could potentially explain the difference in 
responder-rate in the two groups. The positive effect of high age on the 
willingness to participate in surveys have been demonstrated in other 
studies244,245. Studies have shown high age to be a protective factor of chronic 
postoperative pain93,203. Hence, if all non-responders had indeed responded, 
this would theoretically have lowered the mean age of the sample, thereby 
hypothetically increasing the prevalence of chronic postoperative pain in our 
sample. 
 
If the reason for not responding to the questionnaire is in some way related to 
the outcome measure, this could generate bias in the measure of 
association246. That is, if the non-responders either had too much pain to fill 
out the questionnaire or it did not seem relevant to fill out the questionnaire 
since the non-responders did not have any pain at all. Evidently, this can only 
be considered as hypothetical theories. 
 
From the tumor characteristics in table 3 we can conclude that the distribution 
of tumor type, grade and FIGO stage of the responders are highly comparable 
to national- and international reports8,10, thus indicating that our sample is 
representative in that respect. 
 
Effect Measure Modification 
As stated in section ‘3.7.1. Peri- and Postoperative Drug Dose Regimen’, all 
study participants received a uniform dose of 300 mg Gabapentin p.o. 30 
minutes prior to the surgical procedure as an integrated part of the drug dose 
regimen at our facility (and not specific to this research protocol). Some 
studies have shown Gabapentin reduces the risk of acute- and chronic 
postoperative pain, while other studies have shown it merely decreases the 
consumption of opioids in the immediate postoperative period247–250. As the 
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pharmacologic effect of Gabapentin is caused by an influx of calcium in the 
terminals of primary afferent neurons in the dorsal horn of the spinal cord, the 
potential effect of Gabapentin is most likely derived from a direct alteration in 
the causative pathway to development of chronic postoperative pain251,252. As 
such, Gabapentin should be considered as potential effect measure modifier 
(and not a confounder).  However, since all study participants received the 
same dose of Gabapentin, we would expect this effect measure modification 
to be equally distributed in both groups (chronic pain and no chronic pain). 
Nevertheless, the use of Gabapentin in this study should be kept in mind when 
comparing the results to other studies not utilizing Gabapentin in their 
standard drug dose regimen. 
 
Confounding 
Confounding can be described as a confusion of effects200.  A confounder is 
associated with both the exposure and the outcome but does not lie on the 
causative pathway200,253,254. 
 
As stated previously, the unadjusted OR for preoperative pelvic pain as a risk 
factor for development of chronic postoperative pain was 8.81 (95% CI 3.43-
22.38) while the adjusted OR was 4.99 (95% CI 4.15-5.83). In the unadjusted 
OR we merely consider the effect of a single variable (preoperative pelvic 
pain), which is too simple an approach in the case of a complex outcome like 
chronic postoperative pain. As shown in section 1.3.1., a multitude of factors 
affect the development and perpetuation of chronic postoperative pain. For 
that reason, in addition to preoperative pelvic pain, we also included the 
variables acute postoperative pain, age and educational level (as a surrogate 
marker for socioeconomic status119) in the binary logistic regression model in 
table 7, model 2.  
 
Conversely, we did not control for other possible confounding variables like 
comorbidity (including psychological traits like pain catastrophizing), adjuvant 
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therapy (i.e. chemotherapy in advanced stages of disease), smoking status or 
use of analgesics and prescription drugs. As a result, some degree of 
confounding is highly plausible. An example could be comorbidity as a 
confounder. As stated in section ‘1.3.1. Factors affecting Postoperative Pain’, 
comorbidity is associated with an increased risk of chronic pain conditions, 
including chronic postoperative pain as well as an increased risk of 
cancer124,125,255. Consequently, this unadjusted confounding could lead to a 
distortion of the associations in our model, e.g. by overestimating preoperative 
pelvic pain as a risk factor. Smoking as a confounding variable will be 
discussed in section ‘5.6.3. Study III’. 
 
5.6.2. STUDY II 
Information Bias 
As Study II was a nested case-control study within the cohort defined by Study 




The storage of blood and tissue in The Danish Cancer Biobank (DCB) is 
voluntary - nevertheless, the vast majority of patients chooses to do so, 
including the study participants of Study II, where twenty-six of the thirty-one 
patients (83.9%) with chronic postoperative pain had samples stored in the 
DCB (fig. 13). As the samples were obtained preoperatively, the choice of 
having samples stores could not be affected by the outcome (chronic 
postoperative pain), and in that respect, no sampling bias would occur. Yet, 
the choice of having biobank samples stored in general might be affected by 
the ‘healthy worker effect’, where certain individuals (with a healthy life-style 
and an interest in health science) are more prone to participating in such 
research biobanks than others (with a less healthy life-style). Therefore, Study 
II could have an inherent sampling bias200,256. 
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Of far greater significance, however, was the fact that we matched the cases 
with chronic postoperative pain on age and BMI in a 1:2 ratio with controls 
without chronic postoperative pain. Even though this was done with the best 
intent to minimize the risk of confounding, this could in fact introduce sample 
selection bias. This somewhat counterintuitive effect arises as the matching is 
done in an effort to ensure that the distributions of the selected variables are 
identical across outcome groups. By ‘homogenizing’ the groups you obscure 
the effect of the variables you matched on, in this case, age and BMI200,257. As 
a result of this overmatching, the external validity is weakened. 
 
The tumor characteristics of the study participants in table 8 demonstrates  
that the distribution of tumor type, grade and FIGO stage are comparable to 
the distributions found in national- and international settings, thereby 
indicating that the sample is representative in that respect8,10. 
 
5.6.3. STUDY III 
As described in section 5.5., Study III may suffer from being underpowered 
and thereby increasing the risk of a type II error. This could have been 
circumvented by two measures: either include study participants over a longer 
time period or include study participants from multiple centers - or do both. 
The inclusion period of Study III was 41 months which was the longest feasible 
time period in this PhD project. The other option was to enroll study 
participants from multiple centers, which was abandoned during the design 
phase of the study due to the costs of having multiple sets of advanced QST 
equipment at the different centers, as well as reluctance to introduce bias 
through possible interobserver variance and the dissimilarities of the surgical 
algorithms at the different centers. Nonetheless, the fact that this study was 






Study III also utilized the same questionnaire as Study I-II. As a consequence, 
most of the issues regarding information bias including differential and non-
differential misclassification also applies to Study III. In one important aspect, 
however, Study III differentiates from Study I-II. Being a prospective study, the 
questionnaire in Study III was filled out by the study participants 6 months after 
the surgical procedure, thereby minimizing the potential issue of recall bias, 
as compared to the mean follow-up time in Study I of 2.9 years. In the planning 
of Study III, we considered asking the study participants to fill out the first part 
of the questionnaire, concerning the preoperative period, before the surgical 
procedure and thereby minimize the risk of recall bias further. This idea was 
abandoned as splitting up the questionnaire would require a validation 
process and could make the comparison of the results to Study I problematic. 
 
In Study III, all study participants were informed, included and tested by the 
same examiner (Søren Lunde) according to a standardized algorithm. This 
ensured that all study participants were given the exact same instructions prior 
to QST testing and that all tests were performed identically, thus minimizing 
intraobserver variance and eliminating interobserver variance. 
 
Selection Bias 
The inclusion of study participants to Study III was consecutive throughout the 
study period. Of the one-hundred-and-fifty-four questionnaires mailed out, 
merely fourteen (9.1%) were not returned. The non-responder analysis did not 
show any statistically significant difference between responders and non-
responders in terms of age, BMI, duration of surgery or blood loss. The tumor 
characteristics of the responders (table 11) furthermore indicated that our 
samples were representative of the population at interest, as the distribution 
of histologic type, grade and FIGO stage were equivalent to the distributions 
found in national and international databases of endometrial cancer8,10. Based 
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on the above, we consider our study sample representative, thereby 
supporting the overall generalizability of Study III. 
 
Effect Measure Modification 
As the peri- and postoperative drug dose regimen was similar to Study I, the 
issue regarding potential effect measure modification due to Gabapentin also 
applies to Study III.   
 
Confounding 
As described by Hernán et al, identification of potential confounding variables 
can be achieved by three different strategies: 1) Stepwise selection, 2) 
Comparing adjusted and unadjusted outcome measures, or 3) By analysing 
the causal relationship and potential confounders258. In the first strategy, all 
study variables are included in a regression model and a (forward or 
backward) stepwise selection performed. If the p value of the association to 
the given variable reaches a predetermined significance level, it is included in 
the final model200,258. In the second strategy, the adjusted and unadjusted 
outcome measures are compared. If the difference exceeds 10%, the variable 
is considered as a confounder258,259. The third and final strategy requires a 
certain level of knowledge to the causal pathway in question, as the variables 
are analysed according to the criteria of a confounding variable (associated 
with both the exposure and the outcome but does not lie on the causative 
pathway)200,253,258. Directed acyclic graphs (DAGs) are often constructed in 
this analytic process, as it allows for a visual representation of the 
interrelationship of the variables in question258,260,261. Additionally, the DAG 
approach has been proposed as a visual aid in complex pathways in order to 
minimize secondary bias introduced by adjusting for covariates262,263. Our 
strategy in Study I-III was a combination of stepwise selection in the 





In the regression model of Study III, the variables Heat Pain Threshold, BMI, 
and preoperative pelvic pain were selected, as we wanted a simple, 
operational model using only preoperative variables and not e.g. the level of 
acute postoperative pain. In parallel to Study I, comorbidity, adjuvant therapy, 
analgesics / prescription drugs and smoking could potentially all act as 
confounders in Study III as well. Regrettably, the smoking status of the study 
participants in Study III was not obtained. However, if we were to conjecture 
what smoking as an uncontrolled confounding variable could entail, we must 
consult the literature. To the best of our knowledge, smoking does not lie on 
the causative pathway to chronic postoperative pain, but interestingly, 
smoking is associated with a decreased risk of endometrial cancer and an 
increased risk of chronic postoperative pain after hysterectomy62,264. 
Furthermore, a large review by Goldenberg et al showed that smoking was a 
surrogate marker for decreased Health-Related Quality of Life and that this 
association was directly related to the number of cigarettes smoked265. 
Thereby, smoking could act as an uncontrolled confounding variable in our 
studies. Additionally, residual confounding from unknown or unmeasured 









CHAPTER 6. CONCLUSION 
Through the studies of this PhD dissertation, we aimed at investigating 
selected aspects of chronic postoperative pain. In Study I we hypothesized 
that development of chronic postoperative pain was associated to the pre- and 
postoperative risk factors: presence of preoperative pelvic pain, acute 
postoperative pelvic pain, age, severity of cancer, operating time, blood loss, 
educational level and employment status (Hypothesis I). Using a survey 
approach, the results showed preoperative pelvic pain and a high level of 
acute postoperative pain to be significant, independent risk factors with an 
adjusted OR of 4.99 (95% CI 4.15-5.83) and 1.27 (95% CI 1.09-1.45), 
respectively. Neither age, severity of cancer, operating time, blood loss, 
educational level nor employment status showed any significant association 
to chronic postoperative pain. Study I further showed a prevalence of chronic 
postoperative pain of 14.9% (95% CI 10.4-20.6). 
 
From a methodological point of view, Study I had several limitations, mainly 
regarding potential information bias as the validation of the questionnaire was 
scarce. Moreover, despite adjusting for some confounders, important 
confounders like comorbidity and smoking were not adjusted for. Finally, it 
would have been ideal to have obtained HRQoL data for a more nuanced 
characterization of the life following surgery for endometrial cancer. 
 
In the highly exploratory Study II, we hypothesized that patients who 
developed chronic postoperative pain had a distinctive preoperative serologic 
composition of lipids, lipoproteins and other low-molecular metabolites, 
compared to patients who did not develop chronic postoperative pain 
(Hypothesis II). Further, we conjectured that these serologic biomarkers of 
lipids, lipoproteins and other low-molecular metabolites were predictive for 
development of chronic postoperative pain (Hypothesis III). Through NMR 
spectroscopy, results showed that we could not discriminate between these 
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two groups when including all ESMO-ESGO-ESTRO risk assessments 
groups, and as such, Hypothesis II and III were rejected. 
 
In Study III we hypothesized that development of chronic postoperative pain 
was associated to the preoperative risk factors: presence of preoperative 
pelvic pain, age, severity of cancer, educational level and employment status 
(Hypothesis IV). A binary logistic regression model established the presence 
of preoperative pelvic pain as a significant, independent risk factor with an OR 
of 6.62 (95% CI 2.26-19.44), while none of the other variables showed any 
association. The prevalence of chronic postoperative pain was found to be 
13.6% (95% CI 8.4-20.4). In Study III, we also hypothesized that quantitative 
sensory testing by handheld algometry, cuff pressure algometry, temporal 
summation of pain, conditioned pain modulation and heat evoked pain could 
predict development of chronic postoperative pain (Hypothesis V). Our results 
demonstrated significant heat pain hyperalgesia in the group of patients that 
would develop chronic postoperative pain at a later stage compared to 
patients that would not develop chronic postoperative pain. However, this 
association between HPT and chronic postoperative pain was non-significant 
in a binary logistic regression model (OR = 0.86 (95% CI 0.72-1.02)), hence 
Hypothesis V was rejected. 
 
Through the studies presented in this PhD dissertation we have contributed to 
the existing body of knowledge concerning chronic postoperative pain 










CHAPTER 7. CLINICAL IMPLICATIONS 
AND FUTURE PERSPECTIVES 
What can we as clinicians learn from these studies - and should the results 
have implications for the clinical practice? The results suggest that the primary 
predisposing risk factor for development of chronic postoperative pain is a 
preexisting pain condition. This strong association has previously been shown 
in several studies after various types of surgical procedures. The results also 
showed, that despite using state-of-the-art techniques like NMR spectroscopy 
and advanced quantitative sensory testing, we were unable to predict the 
development of chronic postoperative pain. Therefore, we as clinicians should 
ensure that we ask the patients about their medical history of chronic pain 
conditions prior to surgery, as this would be the single most important 
predictor for development of chronic postoperative pain. However, as surgery 
is essentially mandatory in case of endometrial cancer, it would be highly 
questionable that any patients would decline surgery on the basis of an 
increased susceptibility to development of chronic postoperative pain. The 
results of these studies do not change the fact, that evidence shows robot-
assisted laparoscopic hysterectomy to be a safe and highly effective treatment 
for endometrial cancer with a low risk of adverse long-term effects. 
 
As stated in section 5.6.1., the methodological issues regarding the 
questionnaire validation necessitates a thorough and systematic validation if 
the questionnaire were to be utilized in future studies. 
 
Chronic pain as a research field is both fascinating and frustrating due to the 
vast number of interrelated pathophysiologic mechanisms of neuronal 
plasticity and nociceptive modulation. The emerging evidence of lipids and 
lipoproteins as nociceptive modulators is extremely fascinating. Despite our 
hypothesis of Study II were rejected, the results were still very thought-
provoking from an explorative angle. The fact, that metabolic profiling by NMR 
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could discriminate between patients with and without chronic postoperative 
pain in a group of patients with low and intermediate risk assessments calls 
for further investigations. Our results from this subgroup analysis support the 
theory that LA and other omega-6 derivatives constitute a pronociceptive 
cellular environment, thus promoting the induction and perpetuation of chronic 
pain. In the optimal setting of a randomized controlled trial, it would be of great 
interest to examine if a preoperative, diet-induced reduction of omega-6 
derivatives in the months prior to the surgical procedure could reduce the 
prevalence of chronic postoperative pain. However, this is not feasible in the 
case of endometrial cancer, seeing that patients are treated within a few days 
from referral. Therefore, this study should focus on chronic postoperative pain 
following hysterectomy on benign indication. In regard to the sample size of 
such a study, this would have the further advantage of a reduced number of 
patients needed to include compared to endometrial cancer patients, as we a 
priori would expect a higher prevalence of chronic postoperative pain in this 
group of patients with leiomyomas, dysmenorrhea or endometriosis. 
 
Another interesting randomized controlled trial would be a preoperative 
randomization to either standard care or an additional epidural analgesic 
algorithm initiated prior to the surgical procedure and maintained for 24 hours 
postoperatively. This would effectively reduce the level of acute postoperative 
pain and thereby conceivably minimize the elicited surgical stress response. 
Consequently, we would hypothesize that the patients treated with the 
epidural analgesic algorithm would exhibit a lower prevalence of chronic 
postoperative pain due to a lesser extent of central sensibilization in the 
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Bemærk, at disse spørgsmål omhandler tiden før operationen. 
 
1) A. Havde du smerter i bækkenregionen (se billedet) før operationen? 
 Ja     q  
 Nej     q gå til spørgsmål 7 
 Husker ikke    q gå til spørgsmål 7 
 

















2) Hvor ofte havde du smerter i bækkenregionen før operationen?  
 1-3 dage om ugen    q  
 4-6 dage om ugen    q  
 Hver dag     q  
 
3) A. Hvad var dit daglige smerteniveau før operationen? (0 er ingen smerte og 10 er 
den værst tænkelige smerte; sæt cirkel om ét nummer) 
 0          1          2          3          4          5          6          7          8          9          10 
  
 B. Hvor stærk var smerten, når den var værst? 











4) Forstyrrede smerten din søvn før operationen? 
 Ja      q  
 Nej      q  
 Husker ikke     q  
  
5) A. Følte du smerte ved nogle af de nedenstående situationer før operationen?  
 
  Ja         Nej       Ved ikke 
Løb  q   q  q 
 
Tætsiddende tøj  q   q  q 
Under samleje  q   q  q 
Ved tunge løft  q   q  q 
 
Andre situationer  q   q  q 
  
B. Hvis ja til ”Under samleje”, påvirkede det så dit samliv? 
 Ja     q 
 Nej     q 
 
6) Hvor meget påvirkede smerten din dagligdag før operationen? 
 Ingen påvirkning    q  
 Nogen     q  
 Meget     q  
 Rigtig meget    q  
  
7) A. Har du haft smerteproblemer andre steder før operationen? (F.eks. hovedpine, 
rygsmerter, brystsmerter, nakkesmerter) 
 Ja     q  
 Nej     q  gå til spørgsmål 8 
 
 B. Hvor var denne smerte lokaliseret?      
 
 C. Har en læge stillet en diagnose på disse smerter? 
 Ja   q hvilken:    








Bemærk, at de næste spørgsmål omhandler tiden efter operationen. 
 
8)  Hvad var dit smerteniveau på dagen efter operationen? 
(0 er ingen smerte og 10 er den værst tænkelige smerte; sæt cirkel om ét nummer) 
 0          1          2          3          4          5          6          7          8          9          10 
  
9) A. Har du oplevet vedvarende eller periodevise smerter indenfor de sidste 6 måneder 
i bækkenregionen (se billedet)?  
 Ja    q  
 Nej    q      gå til spørgsmål 14 
 
 B. Hvornår begyndte disse smerter efter operationen:  måneder (0 måneder 
betyder at smerterne har været til stede lige siden operationen) 
 


















 D. Hvor ofte har du smerter? 
 1-3 dage om ugen     q 
 4-6 dage om ugen     q  








10) A. Hvad er dit daglige smerteniveau?  
(0 er ingen smerte og 10 er den værst tænkelige smerte; sæt cirkel om ét nummer) 
 0          1          2          3          4          5          6          7          8          9          10 
  
 B. Hvor stærk er smerten, når den er værst? 
 0          1          2          3          4          5          6          7          8          9          10 
  
11) A. Føler du øget smerte ved en eller flere af følgende situationer?  
 
  Ja         Nej      Ved ikke 
Løb  q   q  q 
 
Tætsiddende tøj  q   q  q 
Under samleje  q   q  q 
Ved tunge løft  q   q  q 
 
Andre situationer  q   q  q 
  
B. Hvis ja til ”Under samleje”, påvirker det så dit samliv? 
 Ja      q 
 Nej      q 
  
12)  Har smerten forstyrret din søvn indenfor de sidste 6 måneder? 
 Ja      q  
 Nej      q  
  
13) A. Har du haft smerteproblemer andre steder indenfor de sidste 6 måneder? (f.eks. 
hovedpine, rygsmerter, brystsmerter, nakkesmerter) 
 Ja      q  
 Nej      q gå til spørgsmål 15 
 
 B. Hvor er smerten lokaliseret?     
 
 C. Har en læge stillet en diagnose på disse smerter? 
 Ja    q hvilken:    









14) A. Hvordan er din arbejdssituation? 
Fuldtidsjob q Førtidspensioneret q Hjemmearbejdende q 
Deltidsjob q Pensioneret q Andre:  
Uden arbejde q Studerende q   
 
 B. Hvad er dit uddannelsesniveau? 
Folkeskole / Mellemskole q Mellemlang videregående udd. q 
Gymnasial (HF, STX, HTX, HHX) q Lang videregående udd. q 
Erhvervsfaglig uddannelse (HG) q Forskeruddannelse (Ph.D.)  q 
Kort videregående uddannelse q Andre:  
  
 C. Hvilken alder har du?   år  
 
 D. Hvor høj er du?    cm    
                                                                                
E. Hvor meget vejer du?   kg 
F. Hvor mange børn har du født?                   
     Heraf antal fødsler gennem skeden?        
     Heraf antal fødsler ved kejsersnit?           
 
 
Mange tak, fordi du tog dig tid til at besvare dette spørgeskema.  
Send venligst skemaet retur i medfølgende frankerede svarkuvert. Når du gør dette, giver du 
samtidig samtykke til vi må benytte spørgeskemaets informationer i vores studie.  
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